CUMULATIVE SUPPLEMENT 11

JAN'92-NOV'92

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

Cumulative Supplement 11

November 1992

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

12TH EDITION

CUMULATIVE SUPPLEMENT 11

NOVEMBER 1992

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 12th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (⧫) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∋ " symbol to designate their non-marketed status. All products having a " ∋ " symbol in the 12th Cumulative Supplement of the 12th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 13th Edition.

1.2 CEFADROXIL/CEFADROXIL HEMIHYDRATE ACTIVE INGREDIENT HEADING

The active ingredient heading Cefadroxil/Cefadroxil Hemihydrate replaces the active ingredient heading Cefadroxil which is currently listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, 12th Edition. All products which are listed under Cefadroxil (which is understood to be the monohydrate form) in the 12th Edition will now be listed along with the newly approved duplicate drug products under the new active ingredient, Cefadroxil/Cefadroxil Hemihydrate.

1.3 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.4 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BARNES HIND PHARMACEUTICALS INC (BARNES HIND)	SOLA BARNES HIND (SOLA BARNES HIND)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
MERCK SHARP AND DOHME RESEARCH LABS DIV MERCK AND CO INC (MSD)	MERCK RESEARCH LABORATORIES DIV MERCK AND CO INC (MERCK)
NORWICH EATON PHARMS INC SUB PROCTOR & GAMBLE CO (NORWICH EATON)	PROCTER & GAMBLE PHARMACEUTICALS INC (P&G)
OFFICE SURGEON GENERAL DEPT ARMY (DEPT ARMY)	OFFICE SURGEON GENERAL DEPT ARMY (US ARMY)
RECKITT AND COLMAN PHARMACEUTICALS INC (R & C)	RECKITT AND COLMAN PHARMACEUTICALS INC (RECKITT AND COLMAN)
SCHWARZ PHARMACEUTICALS INC (SCHWARZ)	SCHWARZ PHARMACEUTICALS INC (SCHWARZ PHARMA)
SOLOPAK LABORATORIES (SOLOPAK)	SMITH AND NEPHEW SOLOPAK DIVISION OF SMITH AND NEPHEW (SMITH NEPHEW SOLOPAK)
VICKS HEALTH CARE DIV RICHARDSON VICKS INC (VICKS HLTH CARE)	VICKS HEALTH CARE DIV RICHARDSON VICKS INC (VICKS HEALTH CARE)
WHITBY PHARMACEUTICALS INC (WHITBY PHARMS)	WHITBY PHARMACEUTICALS INC (WHITBY)
US CHEMICAL MARKETING GROUP INC (US CHEM MKTG)	US CHEMICAL MARKETING GROUP INC (US CHEM)

1.5 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)
LACTULOSE SYRUP (SYRUP; ORAL)	LACTULOSE SOLUTION (SOLUTION; ORAL)
LACTULOSE SYRUP (SYRUP; ORAL, RECTAL)	LACTULOSE SOLUTION (SOLUTION; ORAL, RECTAL)
NONE (SYRUP; ORAL)	METOCLOPRAMIDE ORAL SOLUTION (SOLUTION; ORAL)

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1991) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1991	MAR 1992	JUN 1992	SEP 1992
DRUG PRODUCTS LISTED	9584	9473	9476	9501
SINGLE SOURCE	2187 (22.8%)	2222 (23.4%)	2227 (23.5%)	2227 (23.4%)
MULTISOURCE	7397 (77.2%)	7251 (76.6%)	7249 (76.5%)	7274 (76.6%)
THERAPEUTICALLY EQUIVALENT	6580 (68.7%)	6510 (68.7%)	6494 (68.5%)	6518 (68.6%)
NOT THERAPEUTICALLY EQUIVALENT	664 (6.9%)	592 (6.3%)	595 (6.3%)	590 (6.2%)
EXCEPTIONS'	153 (1.6%)	149 (1.6%)	160 (1.7%)	166 (1.8%)
NEW MOLECULAR ENTITIES APPROVED	--	4	2	8
NUMBER OF APPLICANTS	430	437	455	471

'Amino acid-containing products of varying composition (see Introduction, page xvi of the List).

ACETAMINOPHEN; BUTALBITAL

ACETAMINOPHEN; CODEINE PHOSPHATE

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

AB	MIKART	325MG;50MG¤	N89987 001	OCT 26, 1992
AB		650MG;50MG¤	N89988 001	OCT 26, 1992

SEDAPAP

AB	+ MAYRAND	650MG;50MG	N88944 001	OCT 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

	+ SANDOZ	325MG;50MG;40MG;30MG¤	N20232 001	JUL 30, 1992

ACETAMINOPHEN; CODEINE PHOSPHATE

ELIXIR; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	MIKART	120MG/5ML;12MG/5ML¤	N89450 001	OCT 27, 1992

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	PHARM BASICS	120MG/5ML;12MG/5ML	N87006 001	
/AA/	/PHARM BASICS/	/120MG/5ML;12MG/5ML/	/N87006/001/	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>DLT >/AA/	/CHARLOTTE/	/300MG;15MG/	/N89990/001/	/SEP/30,/1988/
>DLT >				
>DLT >/AA/		/300MG;30MG/	/N89805/001/	/SEP/30,/1988/
>DLT >				
>DLT >/AA/		/300MG;60MG/	/N89828/001/	/SEP/30,/1988/
>DLT >				
	ə EON LABS	300MG;15MG	N87433 001	
	ə	300MG;30MG	N85917 001	
	ə	300MG;60MG	N87423 001	
AA	GENEVA	300MG;30MG¤	N81250 001	JUL 16, 1992
AA		300MG;60MG¤	N81249 001	JUL 16, 1992
	ə PARKE DAVIS	300MG;15MG	N85992 001	
	ə	300MG;30MG	N85218 002	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>ADD > AA	VINTAGE	300MG;15MG	N89990 001	SEP 30, 1988
>ADD >				
>ADD > AA		300MG;30MG	N89805 001	SEP 30, 1988
>ADD >				
>ADD > AA		300MG;60MG	N89828 001	SEP 30, 1988
>ADD >				
	/ə/VITARINE/	/300MG;15MG/	/N87433/001/	
	/ə/	/300MG;30MG/	/N85917/001/	
	/ə/	/300MG;60MG/	/N87423/001/	

ACETAMINOPHEN W/ CODEINE PHOSPHATE

/AA/	/CHELSEA/	/300MG;15MG/	/N87277/001/	/MAY/26,/1982/
/AA/		/300MG;30MG/	/N87276/001/	/MAY/26,/1982/
/AA/		/300MG;60MG/	/N87275/001/	/MAY/26,/1982/
	ə CHELSEA	300MG;15MG	N87277 001	MAY 26, 1982
	ə	300MG;30MG	N87276 001	MAY 26, 1982
	ə	300MG;60MG	N87275 001	MAY 26, 1982
/AA/	/PARKE/DAVIS/	/300MG;15MG/	/N85992/001/	
/AA/		/300MG;30MG/	/N85218/002/	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

ELIXIR; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MIKART	500MG/15ML;5MG/15ML¤	N81226 001	OCT 27, 1992
	500MG/15ML;5MG/15ML¤	N89557 001	APR 29, 1992
	500MG/15ML;7.5MG/15ML¤	N81051 001	AUG 28, 1992

TABLET; ORAL

>DLT >	/HYDROCODONE/			
>DLT >/AA/	/CHARLOTTE/	/500MG;5MG/	/N89971/001/	/DEC/02,/1988/
>DLT >				

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>DLT >/AA/	/CHARLOTTE/	/500MG;5MG/	/N89831/001/	/SEP/07,/1988/
>DLT >				

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MIKART	500MG;5MG¤	N89697 001	
			JAN 28, 1992	
		650MG;10MG¤	N81223 001	
			MAY 29, 1992	
/B*/	/PHARM/BASICS/	/500MG;5MG/	/N89291/001/	
			/MAY/29,/1987/	
	ə PHARM BASICS	500MG;5MG	N89291 001	
			MAY 29, 1987	

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>ADD> AA	VINTAGE	500MG;5MG	N89831 001	
>ADD>			SEP 07, 1988	
>ADD> AA		500MG;5MG	N89971 001	
>ADD>			DEC 02, 1988	

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HCL AND ACETAMINOPHEN

AA	MYLAN	650MG;65MG	N83978 001	
	ə	325MG;32MG	N83689 001	
	/PROPOXYPHENE HCL W/ APAP/			
/AA/	/MYLAN/	/650MG;65MG/	/N83978/001/	
		/325MG;32MG/	/N83689/001/	

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

BOROFAIR

/AT/	/PHARMAFAIR/	/2%/	/N88606/001/	
			/AUG/21,/1985/	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

AT	PHARMAFAIR	2%;0.79%	N88606 001	
			AUG 21, 1985	

DOMEBORO

AT	MILES	2%;0.79%	N84476 001	
		/2%;0.79%/	/N84476/001/	

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

/B*/	/PHARM/BASICS/	/250MG/	/N70753/001/	
			/NOV/03,/1986/	
/B*/		/500MG/	/N70754/001/	
			/NOV/03,/1986/	
	ə PHARM BASICS	250MG	N70753 001	
			NOV 03, 1986	
	ə	500MG	N70754 001	
			NOV 03, 1986	

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	CETUS BEN VENUE	10%¤	N72323 001	
			APR 30, 1992	
AN		20%¤	N72324 001	
			APR 30, 1992	
AN	ROXANE	10%¤	N72621 001	
			SEP 30, 1992	
AN		20%¤	N72622 001	
			SEP 30, 1992	

MUCOMYST

AN	APOTHECON	10%	N13601 002	
AN		20%	N13601 001	
/AN/	/MEAD/JOHNSON/	/10%/	/N13601/002/	
/AN/		/20%/	/N13601/001/	

MUCOSIL-10

AN	DEY	10%	N70575 001	
			OCT 14, 1986	

MUCOSIL-20

AN	DEY	20%	N70576 001	
			OCT 14, 1986	
	/MUCOSOL-10/			
/AN/	/DEY/	/10%/	/N70575/001/	
			/OCT/14,/1986/	
	/MUCOSOL-20/			
/AN/	/DEY/	/20%/	/N70576/001/	
			/OCT/14,/1986/	

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	DEY	EQ 0.083% BASE¤	N72652 001	
			FEB 21, 1992	

ALBUTEROL SULFATE

AMIKACIN SULFATE

DOMEBORO

AT MILES 2%;0.79% N84476 001

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN DEY EQ 0.083% BASE¤ N72652 001 FEB 21, 1992

ALBUTEROL SULFATE

SOLUTION; INHALATION

PROVENTIL

AN SCHERING EQ 0.083% BASE N19243 002 JAN 14, 1987

VENTOLIN

AN GLAXO EQ 0.083% BASE¤ N19773 001 APR 23, 1992

SYRUP; ORAL

ALBUTEROL SULFATE

AA LEMMON EQ 2MG BASE/5ML¤ N73419 001 MAR 30, 1992

TABLET; ORAL

ALBUTEROL SULFATE

AB MD PHARM EQ 2MG BASE¤ N73120 001 SEP 29, 1992

AB EQ 4MG BASE¤ N73121 001 SEP 29, 1992

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME 10 UNITS/ML¤ N20057 004 MAY 08, 1992

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

/AB/ /BOLAR/ /100MG/ /N18241/001/ /NOV/16,/1984/

∂ BOLAR 100MG N18241 001 NOV 16, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN

AP ELKINS SINN EQ 50MG BASE/ML¤ N63274 001 MAY 18, 1992

AP EQ 250MG BASE/ML¤ N63275 001 MAY 18, 1992

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKIN

AP BRISTOL EQ 50MG BASE/ML N50495 001

AP EQ 50MG BASE/ML N62562 001 SEP 20, 1984

AP EQ 250MG BASE/ML N50495 002

AP EQ 250MG BASE/ML N62562 002 SEP 20, 1984

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

/AMINOSYN/4.25%/W//DEXTROSE/25%/IN/PLASTIC/CONTAINER/ /ABBOTT/ /4.25%;25GM/100ML/ /N19119/001/ /OCT/11,/1984/

∂ ABBOTT 4.25%;25GM/100ML N19119 001 OCT 11, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

/INJECTABLE;/INJECTION/ /AMINOSYN/3.5%/M/ /ABBOTT/ /3.5%;21MG/100ML;128MG/100ML;/ /234MG/100ML/ /N17789/001/

∂ ABBOTT 3.5%;21MG/100ML;128MG/100ML; 234MG/100ML N17789 001

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

>DLT >/AP/ /LYPHOMED/ /25MG/ML/ /N87250/001/ /JAN/06,/1982/

>DLT >

>ADD >

>ADD > ∂ LYPHOMED 25MG/ML N87250 001 JAN 06, 1982

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	AMITRIL			
AB	WARNER/CHILCOTT	10MG	N83939	001
AB		25MG	N83937	001
AB		50MG	N83938	002
AB		75MG	N84957	001
AB		100MG	N85093	001
AB		150MG	N86295	001
	∂ WARNER CHILCOTT	10MG	N83939	001
	∂	25MG	N83937	001
	∂	50MG	N83938	002
	∂	75MG	N84957	001
	∂	100MG	N85093	001
	∂	150MG	N86295	001

AMITRIPTYLINE HCL

BP	PAR	10MG	N88697	001 SEP 25, 1984
BP		25MG	N88698	001 SEP 25, 1984
BP		50MG	N88699	001 SEP 25, 1984
BP		75MG	N88700	001 SEP 25, 1984
BP		100MG	N88701	001 SEP 25, 1984
BP		150MG	N88702	001 SEP 25, 1984
	∂ PAR	10MG	N88697	001 SEP 25, 1984
	∂	25MG	N88698	001 SEP 25, 1984
	∂	50MG	N88699	001 SEP 25, 1984
	∂	75MG	N88700	001 SEP 25, 1984
	∂	100MG	N88701	001 SEP 25, 1984
	∂	150MG	N88702	001 SEP 25, 1984

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

	CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL			
B*	PHARM BASICS	EQ 12.5MG BASE;5MG	N70477	001 JAN 12, 1988
B*		EQ 25MG BASE;10MG	N70478	001 JAN 12, 1988
	∂ PHARM BASICS	EQ 12.5MG BASE;5MG	N70477	001 JAN 12, 1988
	∂	EQ 25MG BASE;10MG	N70478	001 JAN 12, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	PERPHENAZINE AND AMITRIPTYLINE HCL			
∂	CHELSEA	50MG;4MG	N71558	001 MAR 02, 1987

AMLODIPINE BESYLATE

TABLET; ORAL

	NORVASC			
+	PFIZER	EQ 10MG BASE¤	N19787	003 JUL 31, 1992
		EQ 2.5MG BASE¤	N19787	001 JUL 31, 1992
		EQ 5MG BASE¤	N19787	002 JUL 31, 1992

AMOXAPINE

TABLET; ORAL

	AMOXAPINE			
AB	DANBURY	25MG¤	N72688	001 AUG 28, 1992
AB		50MG¤	N72689	001 AUG 28, 1992
AB		100MG¤	N72690	001 AUG 28, 1992
AB		150MG¤	N72691	001 AUG 28, 1992

AMOXICILLIN

CAPSULE; ORAL

POLYMOX

AB	BRISTOL MYERS	250MG¤	N63099 001 MAR 20, 1992
AB		500MG¤	N63099 002 MAR 20, 1992

UTIMOX

AB	PARKE/DAVIS	250MG	N62107 001
AB		500MG	N62107 002
ə	PARKE DAVIS	250MG	N62107 001
ə		500MG	N62107 002

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB	CLONMEL	125MG/5ML	N62927 001 NOV 25, 1988
AB		250MG/5ML	N62927 002 NOV 25, 1988

UTIMOX

AB	PARKE/DAVIS	125MG/5ML	N62127 001
AB		250MG/5ML	N62127 002
ə	PARKE DAVIS	125MG/5ML	N62127 001
ə		250MG/5ML	N62127 002

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	PHARMA TEK	50MG/VIAL¤	N63206 001 APR 29, 1992

AMPICILLIN SODIUM

INJECTABLE; INJECTION

POLYCILLIN-N

AP	BRISTOL	EQ 125MG BASE/VIAL	N50309 001
AP		EQ 250MG BASE/VIAL	N50309 002
AP		EQ 500MG BASE/VIAL	N50309 003
AP		EQ 1GM BASE/VIAL	N50309 004
AP		EQ 2GM BASE/VIAL	N50309 005
ə	BRISTOL	EQ 125MG BASE/VIAL	N50309 001
ə		EQ 250MG BASE/VIAL	N50309 002
ə		EQ 500MG BASE/VIAL	N50309 003
ə		EQ 1GM BASE/VIAL	N50309 004
ə		EQ 2GM BASE/VIAL	N50309 005

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

AB	PARKE/DAVIS	EQ 250MG BASE	N62041 001
AB		EQ 500MG BASE	N62041 002
ə	PARKE DAVIS	EQ 250MG BASE	N62041 001
ə		EQ 500MG BASE	N62041 002

POLYCILLIN

AB	+ BRISTOL	EQ 250MG BASE	N50310 001
AB		EQ 250MG BASE	N61392 001
AB	+ BRISTOL	EQ 250MG BASE	N61392 001
AB		EQ 500MG BASE	N50310 002
ə		EQ 250MG BASE	N50310 001
ə		EQ 500MG BASE	N50310 002

POWDER FOR RECONSTITUTION; ORAL

AMCILL

AB	PARKE/DAVIS	EQ 125MG BASE/5ML	N62030 001
AB		EQ 250MG BASE/5ML	N62030 002
ə	PARKE DAVIS	EQ 125MG BASE/5ML	N62030 001
ə		EQ 250MG BASE/5ML	N62030 002

POLYCILLIN

AB	BRISTOL	EQ 100MG BASE/ML	N50308 004
AB		EQ 100MG BASE/ML	N61394 001
ə	BRISTOL	EQ 100MG BASE/ML	N50308 004
		EQ 100MG BASE/ML	N61394 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

POLYCILLIN-PRB

/AB/	/BRISTOL/	/EQ 3.5GM BASE/BOT; 1GM/BOT/	/N50457/001/
/AB/		/EQ 3.5GM BASE/BOT; 1GM/BOT/	/N61898/001/
AB +	BRISTOL	EQ 3.5GM BASE/BOT; 1GM/BOT	N61898 001
	∂	EQ 3.5GM BASE/BOT; 1GM/BOT	N50457 001

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

/BUTALBITAL; ASPIRIN AND CAFFEINE/

/AB/	/CHELSEA/	/325MG;50MG;40MG/	/N86231/002/ /FEB/12,/1985/
	∂ CHELSEA	325MG;50MG;40MG	N86231 002 FEB 12, 1985

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE COMPOUND

	∂ EON LABS	385MG;30MG;25MG	N71564 001 JUN 23, 1988
/∂/	/VITARINE/	/385MG;30MG;25MG/	/N71564/001/ /JUN/23,/1988/

ORPHENADRINE COMPOUND DOUBLE STRENGTH

	∂ EON LABS	770MG;60MG;50MG	N71565 001 JUN 23, 1988
/∂/	/VITARINE/	/770MG;60MG;50MG/	/N71565/001/ /JUN/23,/1988/

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND 65

> ADD > AA		EON LABS	389MG;32.4MG;65MG	N80044 002 SEP 16, 1983
> ADD >				
> DLT > /AA/		/VITARINE/	/389MG;32.4MG;65MG/	/N80044/002/ /SEP/16,/1983/
> DLT >				

ASPIRIN; MEPROBAMATE

TABLET; ORAL

MEPRO-ASPIRIN

	∂ EON LABS	325MG;200MG	N89127 001 MAR 02, 1987
/∂/	/VITARINE/	/325MG;200MG/	/N89127/001/ /MAR/02,/1987/

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	APOTHECON	50MG¤	N73317 001 MAR 20, 1992
AB		100MG¤	N73318 001 MAR 20, 1992
AB	GENEVA	25MG¤	N74052 001 MAY 01, 1992
AB	IPR	25MG¤	N73646 001 JUL 31, 1992
AB	LEDERLE	25MG¤	N74099 001 APR 28, 1992
AB	MYLAN	50MG¤	N73456 001 JAN 24, 1992
AB		100MG¤	N73457 001 JAN 24, 1992
AB	SCHIAPPARELLI SEARLE	50MG¤	N73676 001 OCT 30, 1992
AB		100MG¤	N73676 002 OCT 30, 1992

TENORMIN

AB	ICI	25MG	N18240 004 APR 09, 1990

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	DANBURY	50MG;25MG¤	N73665 001 JUL 02, 1992
AB		100MG;25MG¤	N73665 002 JUL 02, 1992

TENORETIC 100

AB +	ICI	100MG;25MG	N18760 001 JUN 08, 1984
/AB/ /+/	/STUART/	/100MG;25MG/	/N18760/001/ /JUN/08,/1984/

TENORETIC 50

AB	ICI	50MG;25MG	N18760 002

ATENOLOL; CHLORTHALIDONE

AZITHROMYCIN DIHYDRATE

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
TENORETIC 50
/AB/ /STUART/ /50MG;25MG/ /N18760/002/ /JUN/08,/1984/

> ADD > ATOVAQUONE

> ADD > TABLET; ORAL
> ADD > MEPRON
> ADD > + BURROUGHS WELLCOME 250MG¤ N20259 001
> ADD > NOV 25, 1992

ATROPINE SULFATE

/AEROSOL;/METERED;/INHALATION/
/ATROPINE/SULFATE/
/US/ARMY/ /EQ/0.36MG/BASE/INH/ /N20056/001/ /SEP/19,/1990/

@ US ARMY EQ 0.36MG BASE/INH N20056 001
SEP 19, 1990

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL
/LOMANATE/
/AA/ /BARRE/ /0.025MG/5ML;2.5MG/5ML/ /N85746/001/
@ BARRE 0.025MG/5ML;2.5MG/5ML N85746 001

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
/AA/ /CHELSEA/ /0.025MG;2.5MG/ /N85876/001/
@ CHELSEA 0.025MG;2.5MG N85876 001
DIPHENOXYLATE HCL W/ ATROPINE SULFATE
@ EON LABS 0.025MG;2.5MG N86173 001
/@/VITARINE/ /0.025MG;2.5MG/ /N86173/001/

/AZITHROMYCIN/

/CAPSULE;/ORAL/
/ZITHROMAX/
/+//PFIZER/ /250MG/ /N50670/001/ /NOV/01,/1991/

AZITHROMYCIN DIHYDRATE

CAPSULE; ORAL
ZITHROMAX
+ PFIZER EQ 250MG BASE N50670 001
NOV 01, 1991

AZLOCILLIN SODIUM

INJECTABLE; INJECTION
AZLIN
> DLT > /MILES/ /EQ/3GM/BASE/VIAL/ /N62388/002/ /SEP/08,/1982/
> DLT >
> ADD > @ MILES EQ 3GM BASE/VIAL N62388 002
> ADD > SEP 08, 1982
> DLT > /EQ/3GM/BASE/VIAL/ /N62417/002/ /OCT/12,/1982/
> DLT >
> ADD > @ EQ 3GM BASE/VIAL N62417 002
> ADD > OCT 12, 1982

BACLOFEN

INJECTABLE; INJECTION
LIORESAL
MEDTRONIC 0.5MG/ML¤ N20075 001
JUN 17, 1992
2MG/ML¤ N20075 002
JUN 17, 1992

TABLET; ORAL
BACLOFEN
AB BIOCRAFT 10MG¤ N73043 001
FEB 27, 1992
AB 20MG¤ N73044 001
FEB 27, 1992
@ EON LABS 10MG N71901 001
APR 13, 1988
@ 20MG N71902 001
APR 13, 1988
/B*/ /PHARM/BASICS/ /10MG/ /N71260/001/ /MAY/06,/1988/
/B*/ /20MG/ /N71261/001/ /MAY/06,/1988/
@ PHARM BASICS 10MG N71260 001
MAY 06, 1988
@ 20MG N71261 001
MAY 06, 1988

BACLOFEN

TABLET; ORAL
BACLOFEN

/∂/	/VITARINE/	/10MG/	/N71961/001/ /APR/13,/1988/
/∂/		/20MG/	/N71962/001/ /APR/13,/1988/

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
LOTENSIN HCT

+	CIBA	20MG;25MG¤	N20033 003 MAY 19, 1992
		5MG;6.25MG¤	N20033 001 MAY 19, 1992
		10MG;12.5MG¤	N20033 002 MAY 19, 1992
		20MG;12.5MG¤	N20033 004 MAY 19, 1992

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	MUTUAL PHARM	1MG¤	N81264 001 JAN 23, 1992
AA		2MG¤	N81265 001 JAN 23, 1992
/B*/	/PHARM/BASICS/	/0.5MG/	/N89211/001/ /JUN/14,/1988/
/B*/		/1MG/	/N89212/001/ /JUN/14,/1988/
/B*/		/2MG/	/N89213/001/ /JUN/14,/1988/
	∂ PHARM BASICS	0.5MG	N89211 001 JUN 14, 1988
	∂	1MG	N89212 001 JUN 14, 1988
	∂	2MG	N89213 001 JUN 14, 1988

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

/AB/	/CLAY/PARK/	/EQ 0.05% BASE/	/N72536/001/ /JAN/31,/1990/
B*	CLAY PARK	EQ 0.05% BASE	N72536 001 JAN 31, 1990
AB	TARO	EQ 0.05% BASE¤	N73552 001 APR 30, 1992

OINTMENT; TOPICAL
BETAMETHASONE DIPROPIONATE

/AB/	/CLAY/PARK/	/EQ 0.05% BASE/	/N72526/001/ /JAN/31,/1990/
B*	CLAY PARK	EQ 0.05% BASE	N72526 001 JAN 31, 1990

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE

/AB/	/PHARMAFAIR/	/EQ 0.1% BASE/	/N70485/001/ /MAY/29,/1987/
	∂ PHARMAFAIR	EQ 0.1% BASE	N70485 001 MAY 29, 1987

OINTMENT; TOPICAL
BETAMETHASONE VALERATE

/AB/	/CLAY/PARK/	/EQ 0.1% BASE/	/N71478/001/ /DEC/23,/1987/
B*	CLAY PARK	EQ 0.1% BASE	N71478 001 DEC 23, 1987
/AB/	/PHARMAFAIR/	/EQ 0.1% BASE/	/N70486/001/ /MAY/29,/1987/
	∂ PHARMAFAIR	EQ 0.1% BASE	N70486 001 MAY 29, 1987

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL
KERLEDEX

+	LOREX	10MG;12.5MG¤	N19807 002 OCT 30, 1992
		5MG;12.5MG¤	N19807 001 OCT 30, 1992

BETHANECHOL CHLORIDE

BROMPHENIRAMINE MALEATE

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

> ADD >	∂ EON LABS	5MG	N84353 001	
	∂	10MG	N84378 001	
> ADD >	∂	10MG	N84379 001	
	∂	25MG	N84384 001	
/AA/	/VITARINE/	/25MG/	/N84383/001/	
> DLT >	/∂/	/5MG/	/N84353/001/	
	/∂/	/10MG/	/N84378/001/	
> DLT >	/∂/	/10MG/	/N84379/001/	
	∂ VITARINE	25MG	N84383 001	
	/∂/	/25MG/	/N84384/001/	

BISOPROLOL FUMARATE

TABLET; ORAL
ZEBETA

+	LEDERLE	10MG¤	N19982 001 JUL 31, 1992
		5MG¤	N19982 002 JUL 31, 1992

BITOLTEROL MESYLATE

SOLUTION; INHALATION
TORNALATE

	/STERLING/	/0.2%¤/	/N19548/001/ /FEB/19,/1992/
	STERLING WINTHROP	0.2%¤	N19548 001 FEB 19, 1992

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

/AP/	/LYPHOMED/	/50MG/ML/	/N70134/001/ /FEB/12,/1986/
	∂ LYPHOMED	50MG/ML	N70134 001 FEB 12, 1986

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

/AA/	/PIONEER/PHARMS/	/4MG/	/N88604/001/ /JUL/13,/1984/
	∂ PIONEER PHARMS	4MG	N88604 001 JUL 13, 1984

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HCL KIT
ABBOTT

	0.075%¤	N19978 001 SEP 03, 1992
	0.114%¤	N19978 002 SEP 03, 1992
	0.23%¤	N19978 003 SEP 03, 1992

BUTABARBITAL SODIUM

TABLET; ORAL
BUTABARBITAL SODIUM

	∂ EON LABS	15MG	N85938 001
	∂	30MG	N85934 001
	/∂/VITARINE/	/15MG/	/N85938/001/
	/∂/	/30MG/	/N85934/001/
	SODIUM BUTABARBITAL		
/AA/	/WEST/WARD/	/15MG/	/N85418/001/
/AA/		/30MG/	/N85432/001/
	∂ WEST WARD	15MG	N85418 001
	∂	30MG	N85432 001

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL
STADOL

+	BRISTOL MYERS SQUIBB	1MG/INH	N19890 001 DEC 12, 1991
		/1MG/INH/	/N19890/001/ /DEC/12,/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

	FRESENIUS	18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤	N20171 001 AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

	FRESENIUS	18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤	N20171 002 AUG 19, 1992

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

	FRESENIUS	18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤	N20171 003 AUG 19, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML¤	N20000 001 APR 17, 1992

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	MCGAW	33MG/100ML;30MG/100ML; 860MG/100ML¤	N20002 001 APR 17, 1992

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

/AB/	/PARKE/DAVIS/	/200MG/	/N70429/001/ /JAN/02,/1987/
/B*/	/PHARM/BASICS/	/200MG/	/N70300/001/ /MAY/15,/1986/
	@ PHARM BASICS	200MG	N70300 001 MAY 15, 1986

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

	@ WARNER CHILCOTT	200MG	N70429 001 JAN 02, 1987

TABLET, CHEWABLE; ORAL

EPITOL

AB	LEMMON	100MG¤	N73524 001 JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	LEMMON	10MG;100MG¤	N73618 001 AUG 28, 1992
AB		25MG;100MG¤	N73589 001 AUG 28, 1992
AB		25MG;250MG¤	N73607 001 AUG 28, 1992

SINEMET

AB	MSD	10MG;100MG	N17555 001
AB		25MG;100MG	N17555 003
AB	+	25MG;250MG	N17555 002

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

	@ EON LABS	350MG	N89566 001 AUG 30, 1988
/B*/	/VITARINE/	/350MG/	/N89566/001/ /AUG/30,/1988/

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB	ZENITH	EQ 500MG BASE	N62766 001 MAR 03, 1987
/3/		/EQ/500MG/BASE/	/N62766/001/ /MAR/03,/1987/

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET; ORAL

	CEFADROXIL			
AB	ZENITH	EQ 1GM BASE	N62774 001	APR 08, 1987
/3/		/EQ/1GM/BASE/	/N62774/001/	/APR/08,/1987/

CEFPODOXIME PROXETIL

GRANULE, FOR RECONSTITUTION; ORAL

	BANAN			
AB	SANKYO	EQ 50MG BASE/5ML¤	N50688 002	AUG 07, 1992
AB		EQ 100MG BASE/5ML¤	N50688 001	AUG 07, 1992
	VANTIN			
AB	UPJOHN	EQ 50MG BASE/5ML¤	N50675 001	AUG 07, 1992
AB +		EQ 100MG BASE/5ML¤	N50675 002	AUG 07, 1992

TABLET; ORAL

	BANAN			
AB	SANKYO	EQ 100MG BASE¤	N50687 001	AUG 07, 1992
AB		EQ 200MG BASE¤	N50687 002	AUG 07, 1992
	VANTIN			
AB	UPJOHN	EQ 100MG BASE¤	N50674 001	AUG 07, 1992
AB +		EQ 200MG BASE¤	N50674 002	AUG 07, 1992

CEFPROZIL

POWDER FOR RECONSTITUTION; ORAL

CEFZIL			
+	BRISTOL MYERS SQUIBB 250MG/5ML	N50665 002	DEC 23, 1991
	/250MG/5ML/	/N50665/002/	/DEC/23,/1991/

CEFPROZIL

TABLET; ORAL

CEFZIL			
+	BRISTOL MYERS SQUIBB 500MG	N50664 002	DEC 23, 1991
	/500MG/	/N50664/002/	/DEC/23,/1991/

CEFTAZIDIME

INJECTABLE; INJECTION

/CEPTAZ/			
/GLAXO/	/500MG/VIAL/	/N50646/001/	/SEP/27,/1990/
	/1GM/VIAL/	/N50646/002/	/SEP/27,/1990/
	/2GM/VIAL/	/N50646/003/	/SEP/27,/1990/
	/10GM/VIAL/	/N50646/004/	/SEP/27,/1990/

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ			
AP	GLAXO	1GM/VIAL	N50646 002	SEP 27, 1990
AP		2GM/VIAL	N50646 003	SEP 27, 1990
AP		10GM/VIAL	N50646 004	SEP 27, 1990
		500MG/VIAL	N50646 001	SEP 27, 1990
	PENTACEF			
AP	SMITHKLINE BEECHAM	1GM/VIAL¤	N64006 001	MAR 31, 1992
AP		2GM/VIAL¤	N64006 002	MAR 31, 1992
AP		10GM/VIAL¤	N64008 002	MAR 31, 1992
		6GM/VIAL¤	N64008 001	MAR 31, 1992

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

	ROCEPHIN		
	/ROCHE/	/EQ/250MG/BASE/VIAL/	/N62510/001/
			/MAR/12,/1985/
	ə ROCHE	EQ 250MG BASE/VIAL	N62510 001
			MAR 12, 1985
		/EQ/500MG/BASE/VIAL/	/N62510/002/
			/MAR/12,/1985/
	ə	EQ 500MG BASE/VIAL	N62510 002
			MAR 12, 1985
		/EQ/1GM/BASE/VIAL/	/N62510/003/
			/MAR/12,/1985/
	ə	EQ 1GM BASE/VIAL	N62510 003
			MAR 12, 1985

CEPHALEXIN

CAPSULE; ORAL

> DLT >	/CEPHALEXIN/MONOHYDRATE/		
> DLT > /B*/	/VITARINE/	/EQ/250MG/BASE/	/N62159/001/
> DLT > /B*/		/EQ/500MG/BASE/	/N62159/002/
> ADD >	ə EON LABS	EQ 250MG BASE	N62159 001
> ADD >	ə	EQ 500MG BASE	N62159 002

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

	CEFADYL		
/AP/	/BRISTOL/	/EQ 20GM BASE/VIAL/	/N50446/004/
	BRISTOL	EQ 20GM BASE/VIAL	N50446 004
	CEPHAPIRIN SODIUM		
/AP/	/ELKINS/SINN/	/EQ 500MG BASE/VIAL/	/N62720/001/
			/JUL/02,/1987/
/AP/		/EQ 1GM BASE/VIAL/	/N62720/002/
			/JUL/02,/1987/
/AP/		/EQ 2GM BASE/VIAL/	/N62720/003/
			/JUL/02,/1987/
/AP/		/EQ 20GM BASE/VIAL/	/N62720/004/
			/JUL/02,/1987/
	ə ELKINS SINN	EQ 500MG BASE/VIAL	N62720 001
			JUL 02, 1987
	ə	EQ 1GM BASE/VIAL	N62720 002
			JUL 02, 1987
	ə	EQ 2GM BASE/VIAL	N62720 003
			JUL 02, 1987
	ə	EQ 20GM BASE/VIAL	N62720 004
			JUL 02, 1987

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	CHLORDIAZEPOXIDE HCL		
	ə EON LABS	5MG	N84919 001
	ə	10MG	N84920 001
	ə	25MG	N84823 001
/AB/	/PARKE/DAVIS/	/5MG/	/N85163/001/
/AB/		/10MG/	/N84598/001/
/AB/		/25MG/	/N85164/001/
	ə PARKE DAVIS	5MG	N85163 001
	ə	10MG	N84598 001
	ə	25MG	N85164 001
/AB/	/VITARINE/	/5MG/	/N84919/001/
/AB/		/10MG/	/N84920/001/
/AB/		/25MG/	/N84823/001/
/AB/	/WEST/WARD/	/5MG/	/N85014/001/
/AB/		/10MG/	/N85000/001/
/AB/		/25MG/	/N85294/001/
	ə WEST WARD	5MG	N85014 001
	ə	10MG	N85000 001
	ə	25MG	N85294 001

CHLOROQUINE PHOSPHATE

TABLET; ORAL

	CHLOROQUINE PHOSPHATE		
/AA/	/WEST/WARD/	/EQ 150MG BASE/	/N83082/001/
	ə WEST WARD	EQ 150MG BASE	N83082 001

CHLOROTHIAZIDE

TABLET; ORAL

	CHLOROTHIAZIDE		
	ə EON LABS	250MG	N85485 001
/S/	/VITARINE/	/250MG/	/N85485/001/

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

	CHLORPHENIRAMINE MALEATE		
/AA/	/PIONEER/PHARMS/	/4MG/	/N88556/001/
			/JUL/13,/1984/
	ə PIONEER PHARMS	4MG	N88556 001
			JUL 13, 1984

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
	∂ EON LABS	250MG		N84669 001
/B*/	/PHARM/BASICS/	/100MG/		/N88708/001/ /AUG/30,/1984/
/B*/		/250MG/		/N88709/001/ /AUG/30,/1984/
	∂ PHARM BASICS	100MG		N88708 001 AUG 30, 1984
	∂	250MG		N88709 001 AUG 30, 1984
	/∂/VITARINE/	/250MG/		/N84669/001/

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	EON LABS	50MG		N87118 001
>DLT >/AB/	/PIONEER/PHARMS/	/50MG/		/N89591/001/ /JUL/21,/1988/
>DLT > >ADD > >ADD >	∂ PIONEER PHARMS	50MG		N89591 001 JUL 21, 1988
/AB/	/VITARINE/	/50MG/		/N87118/001/
/AB/	/WARNER/CHILCOTT/	/25MG/		/N87515/001/ /JAN/24,/1983/
/AB/		/50MG/		/N87516/001/ /FEB/09,/1983/
	∂ WARNER CHILCOTT	25MG		N87515 001 JAN 24, 1983
	∂	50MG		N87516 001 FEB 09, 1983
	THALITONE			
/AB/	/BOEHRINGER/INGELHEIM/	/25MG/		/N88051/001/ /NOV/12,/1982/
		/15MG/		/N19574/001/ /DEC/20,/1988/
BX	HORUS	25MG		N88051 001 NOV 12, 1982
		15MG		N19574 001 DEC 20, 1988

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	/ALPHA CHYMAR/			
/AT/	/BARNES/HIND/	/750 UNITS/VIAL/		/N11837/001/
	∂ SOLA BARNES HIND	750 UNITS/VIAL		N11837 001

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	ZOLYSE			
/AT/	/ALCON/	/750 UNITS/VIAL/		/N11903/001/
	ALCON	750 UNITS/VIAL		N11903 001

CINOXACIN

CAPSULE; ORAL

	CINOBAC			
AB	LILLY	250MG		N18067 001
AB	+	500MG		N18067 002
	CINOXACIN			
AB	BIOCRAFT	250MG¤		N73005 001 FEB 28, 1992
AB		500MG¤		N73006 001 FEB 28, 1992

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

	RENACIDIN			
	/GUARDIAN/LABS/	/6.602GM/100ML;198MG/100ML; 3.177GM/100ML/		/N19481/001/ /OCT/02,/1990/
	GUARDIAN LABS	6.602GM/100ML;198MG/100ML; 3.177GM/100ML		N19481 001 OCT 02, 1990

CLEMASTINE FUMARATE

SYRUP; ORAL

	CLEMASTINE FUMARATE			
AA	COPLEY	EQ 0.5MG BASE/5ML¤		N73095 001 APR 21, 1992
	TAVIST			
/AA/	/DORSEY/	/EQ 0.5MG BASE/5ML/		/N18675/001/ /JUN/28,/1985/
AA	SANDOZ	EQ 0.5MG BASE/5ML		N18675 001 JUN 28, 1985

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE

/AB/	/LEMMON/	/1.34MG¤/		/N73282/001/ /JAN/31,/1992/
AB	LEMMON	2.68MG¤		N73283 001 JAN 31, 1992
		1.34MG¤		N73282 001 JAN 31, 1992
	TAVIST			
AB	+ SANDOZ	2.68MG		N17661 001
	TAVIST-1			
/AB/	/DORSEY/	/1.34MG/		/N17661/002/
	∂ SANDOZ	1.34MG		N17661 002

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

/TABLET;/EXTENDED/RELEASE;/ORAL/
/TAVIST/D/

/+//SANDOZ/	/EQ/1MG/BASE;75MG/	/N18298/001/ /DEC/15,/1982/
∂ SANDOZ	EQ 1MG BASE;75MG	N18298 001 DEC 15, 1982

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL

∂ EON LABS	EQ 75MG BASE	N62910 001 JUL 05, 1988
∂	EQ 150MG BASE	N62910 002 JUL 05, 1988
/∂/VITARINE/	/EQ/75MG/BASE/	/N62910/001/ /JUL/05,/1988/
/∂/	/EQ/150MG/BASE/	/N62910/002/ /JUL/05,/1988/

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN

+ UPJOHN	EQ 2% BASE¤		N50680 001 AUG 11, 1992

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	GENSIA	EQ 150MG BASE/ML¤	N63282 001 MAY 29, 1992

SOLUTION; TOPICAL
CLINDA-DERM

AT	PADDOCK	EQ 1% BASE¤	N63329 001 SEP 30, 1992

CLIOQUINOL; HYDROCORTISONE

/CREAM;/TOPICAL/
/VIOFORM-HYDROCORTISONE/

/CIBA/	/3%;0.5%/	/N16412/002/
	/3%;1%/	/N16412/001/

/OINTMENT;/TOPICAL/
/VIOFORM-HYDROCORTISONE/

/∂/CIBA/	/3%;0.5%/	/N16412/004/
	/3%;1%/	/N16412/003/

CLIOQUINOL; NYSTATIN

/OINTMENT;/TOPICAL/
/NYSTAFORM/

/MILES/	/10MG/GM;/ /100,000/UNITS/GM/	/N50235/001/
∂ MILES	10MG/GM; 100,000 UNITS/GM	N50235 001

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE

AB	PHARMACAPS	500MG¤	N73396 001 MAR 20, 1992

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE

AB	PHARMACAPS	500MG		N73396 001 MAR 20, 1992

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

/B*/	/PHARM/BASICS/	/3.75MG/		/N71242/001/ /MAY/20,/1987/
/B*/		/7.5MG/		/N71243/001/ /MAY/20,/1987/
/B*/		/15MG/		/N71244/001/ /MAY/20,/1987/
	ə PHARM BASICS	3.75MG		N71242 001 MAY 20, 1987
	ə	7.5MG		N71243 001 MAY 20, 1987
	ə	15MG		N71244 001 MAY 20, 1987

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

/AB/	/WARNER/CHILCOTT/	/3.75MG/		/N71828/001/ /MAR/03,/1988/
/AB/		/7.5MG/		/N71829/001/ /MAR/03,/1988/
/AB/		/15MG/		/N71830/001/ /MAR/03,/1988/
	ə WARNER CHILCOTT	3.75MG		N71828 001 MAR 03, 1988
	ə	7.5MG		N71829 001 MAR 03, 1988
	ə	15MG		N71830 001 MAR 03, 1988

CLOTRIMAZOLE

CREAM; TOPICAL
LOTRIMIN

/AT//+//SCHERING/		/1%/		/N17619/001/
BX +	SCHERING	1%		N17619 001

MYCELEX

/AT/	/MILES/	/1%/		/N18183/001/
BX	MILES	1%		N18183 001

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
/HISTAFED 'C'/

/AA/	/CENCI/	/10MG/5ML;30MG/5ML;/ /1.25MG/5ML/		/N89018/001/ /JUL/23,/1986/

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

AA	CENCI	10MG/5ML;30MG/5ML; 1.25MG/5ML		N89018 001 JUL 23, 1986

COLCHICINE; PROBENECID

TABLET; ORAL
/PROBEN-C/

/BP/	/CHELSEA/	/0.5MG;500MG/		/N85552/001/
	ə CHELSEA	0.5MG;500MG		N85552 001

PROBENECID AND COLCHICINE

/BP/	/EON/LABS/	/0.5MG;500MG/		/N86130/001/
	ə EON LABS	0.5MG;500MG		N86130 001

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN

/AP/	/LUITPOLD/	/0.03MG/ML/		/N80668/001/
	ə LUITPOLD	0.03MG/ML		N80668 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOPENTOLATE HCL

/AT/	/BARNES/HIND/	/1%/		/N84863/001/
	ə SOLA BARNES HIND	1%		N84863 001

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

>DLT >/AA/	/PIONEER/PHARMS/	/4MG/		/N87839/001/ /FEB/08,/1984/
>DLT >				
>ADD >	ə PIONEER PHARMS	4MG		N87839 001 FEB 08, 1984
>ADD >				

DACARBAZINE

INJECTABLE; INJECTION

	DACARBAZINE			
AP	LYPHOMED	100MG/VIAL	N70962 001	AUG 28, 1986
AP		200MG/VIAL	N70990 001	AUG 28, 1986
	∂ LYPHOMED	100MG/VIAL	N70962 001	AUG 28, 1986
	∂	200MG/VIAL	N70990 001	AUG 28, 1986
	DTIC-DOME			
AP	MILES	100MG/VIAL	N17575 001	
AP		200MG/VIAL	N17575 002	
	MILES	100MG/VIAL	N17575 001	
		200MG/VIAL	N17575 002	

DESFLURANE

LIQUID; INHALATION

	SUPRANE			
+	ANAQUEST	99.9%	N20118 001	SEP 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	DESIPRAMINE HCL			
AB	EON LABS	25MG	N71601 001	JUN 05, 1987
AB		50MG	N71588 001	JUN 05, 1987
AB		75MG	N71602 001	OCT 05, 1987
AB		100MG	N71766 001	OCT 05, 1987
	∂	10MG	N72167 001	FEB 03, 1988
	∂	150MG	N72254 001	FEB 03, 1988

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	DESIPRAMINE HCL			
B*	PHARM BASICS	25MG	N71864 001	SEP 09, 1987
B*		50MG	N71865 001	SEP 09, 1987
B*		75MG	N71866 001	SEP 09, 1987
B*		100MG	N71867 001	SEP 09, 1987
	∂ PHARM BASICS	25MG	N71864 001	SEP 09, 1987
	∂	50MG	N71865 001	SEP 09, 1987
	∂	75MG	N71866 001	SEP 09, 1987
	∂	100MG	N71867 001	SEP 09, 1987
AB	VITARINE	25MG	N71601 001	JUN 05, 1987
AB		50MG	N71588 001	JUN 05, 1987
AB		75MG	N71602 001	OCT 05, 1987
AB		100MG	N71766 001	OCT 05, 1987
	∂	10MG	N72167 001	FEB 03, 1988
	∂	150MG	N72254 001	FEB 03, 1988

DESONIDE

CREAM; TOPICAL

	DESONIDE			
AB	COPLEY	0.05%	N74027 001	SEP 28, 1992
AB	TARO	0.05%	N73548 001	JUN 30, 1992

LOTION; TOPICAL

	DESOWEN			
	OWEN GALDERMA	0.05%	N72354 001	JAN 24, 1992

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

DEXAIR			
/BAUSCH/AND/LOMB/	/EQ/0.1%/PHOSPHATE/		/N88433/001/ /DEC/15,/1983/
PHARMAFAIR	EQ 0.1% PHOSPHATE		N88433 001 DEC 15, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
MCGAW	3.3GM/100ML;75MG/100ML; 300MG/100ML¤	N19630 049 MAY 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
MCGAW	3.3GM/100ML;110MG/100ML; 300MG/100ML¤	N19630 050 MAY 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
MCGAW	3.3GM/100ML;150MG/100ML; 300MG/100ML¤	N19630 051 MAY 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
MCGAW	3.3GM/100ML;220MG/100ML; 300MG/100ML¤	N19630 052 MAY 07, 1992
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
MCGAW	3.3GM/100ML;300MG/100ML; 300MG/100ML¤	N19630 053 MAY 07, 1992

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM				
/AB/	/PARKE/DAVIS/	/5MG/ML/		/N71614/001/ /OCT/22,/1987/
/AP/		/5MG/ML/		/N71613/001/ /OCT/22,/1987/
ə PARKE DAVIS		5MG/ML		N71613 001 OCT 22, 1987
ə		5MG/ML		N71614 001 OCT 22, 1987

DIAZEPAM

TABLET; ORAL

DIAZEPAM				
/AB/	/PARKE/DAVIS/	/2MG/		/N70269/001/ /SEP/04,/1985/
/AB/		/5MG/		/N70210/001/ /SEP/04,/1985/
/AB/		/10MG/		/N70222/001/ /SEP/04,/1985/
/AB/	/PIONEER/PHARMS/	/2MG/		/N70787/001/ /AUG/02,/1988/
/AB/		/5MG/		/N70788/001/ /AUG/02,/1988/
/AB/		/10MG/		/N70776/001/ /AUG/02,/1988/
ə PIONEER PHARMS		2MG		N70787 001 AUG 02, 1988
ə		5MG		N70788 001 AUG 02, 1988
ə		10MG		N70776 001 AUG 02, 1988
ə WARNER CHILCOTT		2MG		N70209 001 SEP 04, 1985
ə		5MG		N70210 001 SEP 04, 1985
ə		10MG		N70222 001 SEP 04, 1985

DIAZOXIDE

INJECTABLE; INJECTION

DIAZOXIDE				
>DLT >/AP/	/LYPHOMED/	/15MG/ML/		/N71519/001/ /AUG/26,/1987/
>DLT > >ADD > >ADD >	ə LYPHOMED	15MG/ML		N71519 001 AUG 26, 1987

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

VOLTAREN			
+ GEIGY	25MG		N19201 001 JUL 28, 1988
+	50MG		N19201 002 JUL 28, 1988
		/25MG/	/N19201/001/ /JUL/28,/1988/
		/50MG/	/N19201/002/ /JUL/28,/1988/

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

		DIETHYLPROPION HCL		
		∂ EON LABS	25MG	N85916 001
		/∂/VITARINE/	/25MG/	/N85916/001/

DIFLORASONE DIACETATE

CREAM; TOPICAL

		FLORONE		
>ADD>	BX +	UPJOHN	0.05%	N17741 001
>ADD>		PSORCON		
>ADD>	BX	DERMIK	0.05%¤	N20205 001 NOV 20, 1992
>ADD>				

DIFLUNISAL

TABLET; ORAL

		DIFLUNISAL		
	AB	LEMMON	250MG¤	N73679 001 JUL 31, 1992
	AB		500MG¤	N73673 001 JUL 31, 1992
>ADD>	AB	ROXANE	250MG¤	N73562 001 NOV 27, 1992
>ADD>	AB		500MG¤	N73563 001 NOV 27, 1992
>ADD>				
		DOLOBID		
	AB	MSD	250MG	N18445 001 APR 19, 1982
	AB +		500MG	N18445 002 APR 19, 1982

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		CARDIZEM CD		
	BC +	MARION MERRELL DOW	180MG	N20062 002 DEC 27, 1991
	BC +		240MG	N20062 003 DEC 27, 1991
	+		120MG¤	N20062 001 AUG 10, 1992
	+		300MG	N20062 004 DEC 27, 1991
			/300MG/	/N20062/004/ /DEC/27,/1991/

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		CARDIZEM SR		
	+	MARION MERRELL DOW	60MG	N19471 001 JAN 23, 1989
	+		90MG	N19471 002 JAN 23, 1989
			/60MG/	/N19471/001/ /JAN/23,/1989/
			/90MG/	/N19471/002/ /JAN/23,/1989/
		DILACOR XR		
	BC	RHONE POULENC RORER	180MG¤	N20092 002 MAY 29, 1992
	BC		240MG¤	N20092 003 MAY 29, 1992
	∂		120MG¤	N20092 001 MAY 29, 1992

INJECTABLE; INJECTION

		CARDIZEM		
		MARION MERRELL DOW	5MG/ML	N20027 001 OCT 24, 1991
			/25MG/VIAL/	/N20027/001/ /OCT/24,/1991/
			/50MG/VIAL/	/N20027/002/ /OCT/24,/1991/

TABLET; ORAL

		CARDIZEM		
>ADD>	AB	MARION MERRELL DOW	30MG	N18602 001 NOV 05, 1982
>ADD>	AB		60MG	N18602 002 NOV 05, 1982
>ADD>	AB		90MG	N18602 003 DEC 08, 1986
>ADD>	AB +		120MG	N18602 004 DEC 08, 1986
		DILTIAZEM HCL		
>ADD>	AB	COPLEY	30MG¤	N74067 001 NOV 05, 1992
>ADD>	AB		60MG¤	N74067 002 NOV 05, 1992
>ADD>	AB		90MG¤	N74067 003 NOV 05, 1992
>ADD>	AB		120MG¤	N74067 004 NOV 05, 1992

DISOPYRAMIDE PHOSPHATE

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

DILTIAZEM HCL

> ADD >				
> ADD >	AB	LEDERLE	30MG¤	N74093 001 NOV 05, 1992
> ADD >				
> ADD >	AB		60MG¤	N74093 002 NOV 05, 1992
> ADD >				
> ADD >	AB		90MG¤	N74093 003 NOV 05, 1992
> ADD >				
> ADD >	AB		120MG¤	N74093 004 NOV 05, 1992
> ADD >				
> ADD >	AB	MYLAN	30MG¤	N73185 001 NOV 05, 1992
> ADD >				
> ADD >	AB		60MG¤	N73186 001 NOV 05, 1992
> ADD >				
> ADD >	AB		90MG¤	N72837 001 NOV 05, 1992
> ADD >				
> ADD >	AB		120MG¤	N72838 001 NOV 05, 1992
> ADD >				

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

AA	EON LABS	25MG	N80845 002
AA		50MG	N80845 001
/AA/	/PIONEER PHARMS/	/25MG/	/N89101 001/ /DEC 20, 1985/
/AA/		/50MG/	/N88880 001/ /DEC 20, 1985/
	ə PIONEER PHARMS	25MG	N89101 001 DEC 20, 1985
	ə	50MG	N88880 001 DEC 20, 1985
/AA/	/VITARINE/	/25MG/	/N88845 002/
/AA/		/50MG/	/N88845 001/

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB	GENEVA	50MG¤	N87562 001 FEB 25, 1992
AB		75MG¤	N87561 001 FEB 25, 1992

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

/B*/	/CHELSEA/	/EQ 100MG BASE/	/N71020 001/ /DEC 01, 1986/
/B*/		/EQ 150MG BASE/	/N71021 001/ /DEC 01, 1986/
/B*/	/INTERPHARM/	/EQ 100MG BASE/	/N71190 001/ /JAN 15, 1987/
/B*/		/EQ 150MG BASE/	/N71191 001/ /JAN 15, 1987/
	ə INTERPHARM	EQ 100MG BASE	N71190 001 JAN 15, 1987
	ə	EQ 150MG BASE	N71191 001 JAN 15, 1987

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

/AP/	/LYPHOMED/	/40MG/ML/	/N70058 001/ /MAR 20, 1985/
/AP/		/80MG/ML/	/N70059 001/ /MAR 20, 1985/
/AP/		/160MG/ML/	/N70364 001/ /DEC 04, 1985/
	ə LYPHOMED	40MG/ML	N70058 001 MAR 20, 1985
	ə	80MG/ML	N70059 001 MAR 20, 1985
	ə	160MG/ML	N70364 001 DEC 04, 1985

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	ROBINS	20MG/ML	N14879 001

DOXAPRAM HCL

AP	STERIS	20MG/ML¤	N73529 001 JAN 30, 1992

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

	ə EON LABS	EQ 50MG BASE	N62780 001 APR 12, 1988
	ə	EQ 100MG BASE	N62227 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

/B*/	/INTERPHARM/	/EQ/50MG/BASE/	/N62763/001/	/SEP/02,/1988/
/B*/		/EQ/100MG/BASE/	/N62763/002/	/SEP/02,/1988/
	ə INTERPHARM	EQ 50MG BASE	N62763 001	SEP 02, 1988
	ə	EQ 100MG BASE	N62763 002	SEP 02, 1988
/AB/	/PARKE/DAVIS/	/EQ 50MG BASE/	/N62594/001/	/DEC/05,/1985/
/AB/		/EQ 100MG BASE/	/N62594/002/	/DEC/05,/1985/
	/3/VITARINE/	/EQ/50MG/BASE/	/N62780/001/	/APR/12,/1988/
	/3/	/EQ/100MG/BASE/	/N62227/001/	
	ə WARNER CHILCOTT	EQ 50MG BASE	N62594 001	DEC 05, 1985
	ə	EQ 100MG BASE	N62594 002	DEC 05, 1985

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE

AB	SIDMAK	EQ 100MG BASE*	N63187 001 JUN 30, 1992

TABLET; ORAL

DOXYCYCLINE HYCLATE

/B*/	/INTERPHARM/	/EQ/100MG/BASE/	/N62764/001/	/SEP/02,/1988/
	ə INTERPHARM	EQ 100MG BASE	N62764 001	SEP 02, 1988
>DLT >/AB/	/MEDICOPHARMA/	/EQ 100MG BASE/	/N62538/001/	/APR/07,/1986/
>DLT > /AB/	/PARKE/DAVIS/	/EQ 100MG BASE/	/N62593/001/	/AUG/28,/1985/
>ADD > AB >ADD >	VINTAGE	EQ 100MG BASE	N62538 001	APR 07, 1986
	ə WARNER CHILCOTT	EQ 100MG BASE	N62593 001	AUG 28, 1985

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

/AP/	/LYPHOMED/	/2.5MG/ML/	/N70992/001/	/NOV/17,/1986/
/AP/		/2.5MG/ML/	/N70993/001/	/NOV/17,/1986/
	ə LYPHOMED	2.5MG/ML	N70992 001	NOV 17, 1986
	ə	2.5MG/ML	N70993 001	NOV 17, 1986
/AP/	/SOLOPAK/	/2.5MG/ML/	/N71750/001/	/SEP/06,/1988/
	ə SOLOPAK	2.5MG/ML	N71750 001	SEP 06, 1988

ENOXACIN

TABLET; ORAL

PENETREX

+	PARKE DAVIS	400MG	N19616 005 DEC 31, 1991
		/400MG/	/N19616/005/ /DEC/31,/1991/

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP	GRAHAM CHEM	0.01MG/ML;2%	N80504 004 OCT 19, 1983
AP		0.02MG/ML;2%	N80504 005 OCT 19, 1983

LIDOCAINE HCL W/ EPINEPHRINE

/AP/	/GRAHAM CHEM/	/0.01MG/ML;2%/	/N80504/004/	/OCT/19,/1983/
/AP/		/0.02MG/ML;2%/	/N80504/005/	/OCT/19,/1983/

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

ALKERGOT

ə EON LABS	0.5MG	N85153 001	
ə	1MG	N87417 001	
/3/VITARINE/ /3/	/0.5MG/ /1MG/	/N85153/001/ /N87417/001/	

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

/ERGOMAR/			
/AA/	/FISONS/	/2MG/	/N87693/001/ /FEB/24,/1983/
	∂ FISONS	2MG	N87693 001 FEB 24, 1983

ERYTHROMYCIN

SOLUTION; TOPICAL

/C-SOLVE-2/			
/AT/	/SYOSSET/	/2%/	/N62468/001/ /JUL/03,/1985/
	C-SOLVE-2		
AT	SYOSSET	2%	N62468 001 JUL 03, 1985
	ERYTHROMYCIN		
AT	PHARM BASICS	2%	N62825 001 OCT 23, 1987
/MYTHROMYCIN/			
/AT/	/PHARM/BASICS/	/2%/	/N62825/001/ /OCT/23,/1987/
	SANSAC		
AT	OWEN GALDERMA	2%	N62522 001 JAN 24, 1985
/SANSACNE/			
/AT/	/OWEN/GALDERMA/	/2%/	/N62522/001/ /JAN/24,/1985/

TABLET, COATED PARTICLES; ORAL

PCE		
ABBOTT	500MG	N50611 002 AUG 22, 1990

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

/E-MYCIN E/			
/AB/	/UPJOHN/	/EQ 200MG BASE/5ML/	/N62198/001/
/AB/		/EQ 400MG BASE/5ML/	/N62198/002/
	∂ UPJOHN	EQ 200MG BASE/5ML	N62198 001
	∂	EQ 400MG BASE/5ML	N62198 002
	ERYTHROMYCIN ETHYLSUCCINATE		
/AB/	/PARKE/DAVIS/	/EQ 200MG BASE/5ML/	/N62231/001/
/AB/		/EQ 400MG BASE/5ML/	/N62231/002/
	∂ PARKE DAVIS	EQ 200MG BASE/5ML	N62231 001
	∂	EQ 400MG BASE/5ML	N62231 002

ESTROPIPATE

TABLET; ORAL

/OGEN/			
/AB/ /AB/ /+/	/ABBOTT/	/0.75MG/ /1.5MG/ /3MG/ /6MG/	/N83220/001/ /N83220/002/ /N83220/003/ /N83220/004/
	OGEN .625		
AB	ABBOTT	0.75MG	N83220 001
	OGEN 1.25		
AB +	ABBOTT	1.5MG	N83220 002
	OGEN 2.5		
	ABBOTT	3MG	N83220 003
	OGEN 5		
	ABBOTT	6MG	N83220 004

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL			
/BP/	/SCHERING/	/0.05MG/	/N05292/002/
	SCHERING	0.05MG	N05292 002
/FEMINONE/			
/BP/	/UPJOHN/	/0.05MG/	/N16649/001/
	∂ UPJOHN	0.05MG	N16649 001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	GENCEPT 0.5/35-21		
AB	GENCON	0.035MG;0.5MG¤	N72692 001 FEB 28, 1992
	GENCEPT 1/35-21		
AB	GENCON	0.035MG;1MG¤	N72693 001 FEB 28, 1992
	GENCEPT 10/11-21		
AB	GENCON	0.035MG;0.5MG AND 1MG¤	N72694 001 FEB 28, 1992
/N.E.E. 1/35 21/			
/AB/	/METROMED/	/0.035MG;1MG/	/N71541/001/ /DEC/14,/1987/
	∂ LPI	0.035MG;1MG	N71541 001 DEC 14, 1987

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	GENCEPT 0.5/35-28			
AB	GENCON	0.035MG;0.5MG¤	N72695 001	FEB 28, 1992
	GENCEPT 1/35-28			
AB	GENCON	0.035MG;1MG¤	N72696 001	FEB 28, 1992
	GENCEPT 10/11-28			
AB	GENCON	0.035MG;0.5MG AND 1MG¤	N72697 001	FEB 28, 1992
	N.E.E. 1/35 28			
AB	METROMED	0.035MG;1MG	N71542 001	DEC 14, 1987
	∂ LPI	0.035MG;1MG	N71542 001	DEC 14, 1987

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

	ORTHO TRI-CYCLEN			
+	JOHNSON RW	0.035MG; 0.18MG,0.215MG,0.25MG¤	N19697 002	JUL 03, 1992

TABLET; ORAL-28

	ORTHO TRI-CYCLEN			
	JOHNSON RW	0.035MG; 0.18MG,0.215MG,0.25MG¤	N19697 001	JUL 03, 1992

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

	PLENDIL			
	MERCK	5MG	N19834 001	JUL 25, 1991
		10MG	N19834 002	JUL 25, 1991

FENOPROFEN CALCIUM

CAPSULE; ORAL

	FENOPROFEN CALCIUM			
AB	HALSEY	EQ 200MG BASE	N72355 001	JUL 05, 1988
AB		EQ 300MG BASE	N72356 001	JUL 05, 1988
> DLT > > DLT > > ADD > > ADD > AB	WARNER CHILCOTT	EQ 200MG BASE	N72946 001	APR 30, 1991

TABLET; ORAL

	FENOPROFEN CALCIUM			
AB	HALSEY	EQ 600MG BASE	N72357 001	JUL 05, 1988

FENTANYL CITRATE

INJECTABLE; INJECTION

	FENTANYL CITRATE			
AP	STERIS	EQ 0.05MG BASE/ML¤	N73488 001	JUN 30, 1992

FINASTERIDE

TABLET; ORAL

	PROSCAR			
+	MSD	5MG¤	N20180 001	JUN 19, 1992

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUONID			
AT	ALLERGAN HERBERT	0.025%	N87156 002	SEP 06, 1984

FLUOCINONIDE

FOLIC ACID

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

/AB/	/CLAY/PARK/	/0.05%/	/N71790/001/ /APR/25,/1988/
B*	CLAY PARK	0.05%	N71790 001 APR 25, 1988
AB	NMC	0.05%¤	N73085 001 FEB 14, 1992

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

>DLT >/AP/ >DLT > >ADD > >ADD >	/ABIC/	/50MG/ML/	/N88929/001/ /MAR/04,/1986/
	∂ ABIC	50MG/ML	N88929 001 MAR 04, 1986
/AP/	/LYPHOMED/	/50MG/ML/	/N89152/001/ /MAR/21,/1986/
/AP/		/50MG/ML/	/N89428/001/ /JAN/12,/1987/
/AP/		/50MG/ML/	/N89519/001/ /MAR/12,/1987/
	∂ LYPHOMED	50MG/ML	N89152 001 MAR 21, 1986
	∂	50MG/ML	N89428 001 JAN 12, 1987
	∂	50MG/ML	N89519 001 MAR 12, 1987

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

/B*/	/PHARM/BASICS/	/15MG/	/N70562/001/ /JUL/09,/1987/
/B*/		/30MG/	/N70563/001/ /JUL/09,/1987/
	∂ PHARM BASICS	15MG	N70562 001 JUL 09, 1987
	∂	30MG	N70563 001 JUL 09, 1987

FOLIC ACID

TABLET; ORAL
FOLIC ACID

	∂ EON LABS	1MG	N84472 001

FOLIC ACID

TABLET; ORAL
FOLIC ACID

/AA/	/LILLY/	/1MG/	/N06135/003/
	∂ LILLY	1MG	N06135 003
>DLT >/AA/ >ADD > AA	/PHOENIX/LABS/	/1MG/	/N86296/001/
	VINTAGE	1MG	N86296 001
	/∂/VITARINE/	/1MG/	/N84472/001/

FURAZOLIDONE

SUSPENSION; ORAL
FUROXONE

+ ROBERTS	50MG/15ML	N11323 002
	/50MG/15ML/	/N11323/002/

TABLET; ORAL
FUROXONE

+ ROBERTS	100MG	N11270 002
	/100MG/	/N11270/002/

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/LYPHOMED/	/10MG/ML/	/N18507/001/ /JUL/30,/1982/
	∂ LYPHOMED	10MG/ML	N18507 001 JUL 30, 1982

TABLET; ORAL
FUROSEMIDE

/AB/	/CHELSEA/	/20MG/	/N18369/001/ /MAY/14,/1982/
/AB/		/40MG/	/N18369/002/ /MAY/14,/1982/
	∂ CHELSEA	20MG	N18369 001 MAY 14, 1982
	∂	40MG	N18369 002 MAY 14, 1982
	∂ EON LABS	40MG	N18750 002 JUL 30, 1984
	/∂/VITARINE/	/40MG/	/N18750/002/ /JUL/30,/1984/

> ADD > GADOTERIDOL

> ADD > INJECTABLE; INJECTION
> ADD > PROHANCE
> ADD > SQUIBB — 279.3MG/ML¤ — N20131 001 NOV 16, 1992
> ADD >

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67
/BS/ /DUPONT/ — /2MCI/ML/ — /N17478/001/
BS DUPONT MERCK — 2MCI/ML — N17478 001

GLYBURIDE

TABLET; ORAL
GLUBATE
BX HOECHST ROUSSEL — 1.5MG¤ — N20055 001 APR 17, 1992
BX — 3MG¤ — N20055 002 APR 17, 1992

GLYNASE
BX UPJOHN — 1.5MG — N20051 001 MAR 04, 1992
BX + — 3MG — N20051 002 MAR 04, 1992

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE PUMP KIT
FERRING — 0.8MG/VIAL — N19687 001 OCT 10, 1989
3.2MG/VIAL — N19687 002 OCT 10, 1989
/JOHNSON/RW/ — /0.8MG/VIAL/ — /N19687/001/ /OCT/10,/1989/
/3.2MG/VIAL/ — /N19687/002/ /OCT/10,/1989/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
ULTRAGRIS-165
AB SIDMAK — 165MG¤ — N62645 001 JUN 30, 1992

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
ULTRAGRIS-330
AB SIDMAK — 330MG¤ — N62646 001 JUN 30, 1992

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL
HALFAN
+ SMITHKLINE BEECHAM — 250MG¤ — N20250 001 JUL 24, 1992

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL
/AB/ /ROYCE/ — /0.5MG/ — /N71722/001/ /DEC/24,/1987/
/AB/ — /1MG/ — /N71723/001/ /DEC/24,/1987/
/AB/ — /2MG/ — /N71724/001/ /DEC/24,/1987/
/AB/ — /5MG/ — /N71725/001/ /DEC/24,/1987/
/AB/ — /10MG/ — /N72121/001/ /DEC/24,/1987/
/AB/ — /20MG/ — /N72122/001/ /DEC/24,/1987/

a ROYCE — 0.5MG — N71722 001 DEC 24, 1987
a — 1MG — N71723 001 DEC 24, 1987
a — 2MG — N71724 001 DEC 24, 1987
a — 5MG — N71725 001 DEC 24, 1987
a — 10MG — N72121 001 DEC 24, 1987
a — 20MG — N72122 001 DEC 24, 1987

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
ULTRAGRIS-165

AB	SIDMAK	165MG¤	N62645 001 JUN 30, 1992	

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

/AP/	/LYPHOMED/	/EQ 5MG BASE/ML	/N71187/001/ /JAN/20,/1987/	
	ə LYPHOMED	EQ 5MG BASE/ML	N71187 001 JAN 20, 1987	

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

/AP/	/LUITPOLD/	/10 UNITS/ML/	/N89063/001/ /OCT/09,/1985/	
/AP/		/100 UNITS/ML/	/N89064/001/ /OCT/09,/1985/	
	ə LUITPOLD	10 UNITS/ML	N89063 001 OCT 09, 1985	
	ə	100 UNITS/ML	N89064 001 OCT 09, 1985	

/HEPARIN LOCK FLUSH PRESERVATIVE FREE/

/AP/	/LYPHOMED/	/10 UNITS/ML/	/N17029/011/ /SEP/22,/1987/	
/AP/		/100 UNITS/ML/	/N17029/012/ /SEP/22,/1987/	
	ə LYPHOMED	10 UNITS/ML	N17029 011 SEP 22, 1987	
	ə	100 UNITS/ML	N17029 012 SEP 22, 1987	

/HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINERS/

/AP/	/LYPHOMED/	/10 UNITS/ML/	/N17029/008/ /SEP/22,/1987/	
/AP/		/100 UNITS/ML/	/N17029/009/ /SEP/22,/1987/	
	ə LYPHOMED	10 UNITS/ML	N17029 008 SEP 22, 1987	> DLT >
	ə	100 UNITS/ML	N17029 009 SEP 22, 1987	> DLT >

HEPARIN SODIUM

/AP/	/LUITPOLD/	/1,000 UNITS/ML/	/N87452/001/ /OCT/31,/1983/	> DLT >
	ə LUITPOLD	1,000 UNITS/ML	N87452 001 OCT 31, 1983	> ADD >

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%

/3/	/ABBOTT/	/10,000/UNITS/100ML/	/N18911/006/ /JAN/30,/1985/	> ADD >
AP	ABBOTT	10,000 UNITS/100ML	N18911 006 JAN 30, 1985	> ADD >

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM 1000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	MCGAW	200 UNITS/100ML¤	N19953 001 JUL 20, 1992

HEPARIN SODIUM 12500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML¤	N19802 001 JUL 20, 1992

HEPARIN SODIUM 20000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	4,000 UNITS/100ML¤	N19952 001 JUL 20, 1992

HEPARIN SODIUM 25000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML¤	N19952 004 JUL 20, 1992
AP		10,000 UNITS/100ML¤	N19952 005 JUL 20, 1992

HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	MCGAW	5,000 UNITS/100ML¤	N19802 005 JUL 20, 1992
AP		10,000 UNITS/100ML¤	N19802 002 JUL 20, 1992

HEPARIN SODIUM 25000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	MCGAW	5,000 UNITS/100ML¤	N19802 003 JUL 20, 1992

HISTRELIN ACETATE

INJECTABLE; INJECTION
SUPPRELIN

/JOHNSON/RW/	/EQ/0.2MG/BASE/ML/	/N19836/001/ /DEC/24,/1991/	> DLT >
	/EQ/0.5MG/BASE/ML/	/N19836/002/ /DEC/24,/1991/	> DLT >
	/EQ/1MG/BASE/ML/	/N19836/003/ /DEC/24,/1991/	> DLT >
ROBERTS	EQ 0.2MG BASE/ML	N19836 001 DEC 24, 1991	> ADD >
	EQ 0.5MG BASE/ML	N19836 002 DEC 24, 1991	> ADD >
	EQ 1MG BASE/ML	N19836 003 DEC 24, 1991	> ADD >

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

/AP/	/CIBA/	/20MG/ML/	/N083303/003/	
	CIBA	20MG/ML	N08303 003	
/AP/	/HYDRALAZINE HCL;/ /LYPHOMED/	/20MG/ML/	/N089532/001/ /AUG/11,/1987/	
	∂ LYPHOMED	20MG/ML	N89532 001 AUG 11, 1987	

TABLET; ORAL

HYDRALAZINE HCL

	∂ EON LABS	50MG	N85088 001	
/AA/	/VANGARD/	/25MG/	/N087712/001/	
	∂ VANGARD	25MG	N87712 001	
	/∂/VITARINE/	/50MG/	/N850088/001/	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

/HYDRAL/

/AB/	/SOLVAY/	/25MG;25MG/	/N087608/001/ /FEB/08,/1982/	
/AB/		/50MG;50MG/	/N087213/001/ /FEB/08,/1982/	
/AB/		/100MG;50MG/	/N087609/001/ /FEB/08,/1982/	

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

AB	SOLVAY	25MG;25MG	N87608 001 FEB 08, 1982
AB		50MG;50MG	N87213 001 FEB 08, 1982
	∂	100MG;50MG	N87609 001 FEB 08, 1982

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDRAP-ES

	∂ EON LABS	25MG;15MG;0.1MG	N84876 001	
	/∂/VITARINE/	/25MG;15MG;0.1MG/	/N084876/001/	

/RESERPINE/HYDRALAZINE/HCL/HYDROCHLOROTHIAZIDE/

/BP/	/DANBURY/	/25MG;15MG;0.1MG/	/N855549/001/	
/BP/		/25MG;15MG;0.1MG/	/N87556/001/	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

BP	DANBURY	25MG;15MG;0.1MG	N85549 001
BP		25MG;15MG;0.1MG	N87556 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP

	∂ EON LABS	25MG;0.1MG	N84617 001
	/∂/VITARINE/	/25MG;0.1MG/	/N84617/001/

SERPASIL-APRESOLINE

/BP/	/CIBA/	/25MG;0.1MG/	/N09296/004/
	CIBA	25MG;0.1MG	N09296 004

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

>_DLT_>	/HYDROCHLOROTHIAZIDE/INTENSOL/			
>_DLT_>	/ROXANE/	/100MG/ML/	/N088588/001/ /JUL/02,/1984/	
>_DLT_>	∂ ROXANE	100MG/ML	N88588 001 JUL 02, 1984	
>_ADD_>				
>_ADD_>				

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	DANBURY	25MG*	N81189 001 JAN 24, 1992
AB		100MG*	N81190 001 JAN 24, 1992
/AB/	/EON/LABS/	/25MG/	/N838999/001/
AB	EON LABS	50MG	N85219 001
	∂	25MG	N83899 001
/AB/	/HEATHER/	/50MG/	/N84135/001/
	∂ HEATHER	50MG	N84135 001
/AB/	/VITARINE/	/50MG/	/N85219/001/
/AB/	/WARNER/CHILCOTT/	/25MG/	/N87586/001/ /MAY/03,/1982/
/AB/		/50MG/	/N87587/001/ /MAY/03,/1982/
	∂ WARNER CHILCOTT	25MG	N87586 001 MAY 03, 1982
	∂	50MG	N87587 001 MAY 03, 1982

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	HYDRO-SERP 25			
	∂ EON LABS	25MG;0.125MG	N84827 001	
/∂/	/VITARINE/	/25MG;0.125MG/	/N84827/001/	
	HYDRO-SERP 50			
	∂ EON LABS	50MG;0.125MG	N85213 001	
/∂/	/VITARINE/	/50MG;0.125MG/	/N85213/001/	
	/SERPASIL-ESIDRIX/#1/			
/BP/	/CIBA/	/25MG;0.1MG/	/N11878/003/	
	∂ CIBA	25MG;0.1MG	N11878 003	
	/SERPASIL-ESIDRIX/#2/			
/BP/	/CIBA/	/50MG;0.1MG/	/N11878/005/	
	∂ CIBA	50MG;0.1MG	N11878 005	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

	MAXZIDE-25			
AB	MYLAN	25MG;37.5MG	N19129 003 MAY 13, 1988	
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
/B*/	/EON/LABS/	/50MG;75MG/	/N71360/001/ /DEC/08,/1987/	
	∂ EON LABS	50MG;75MG	N71360 001 DEC 08, 1987	
AB	GENEVA	25MG;37.5MG‡	N73281 001 APR 30, 1992	

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE			
/AT/	/BAUSCH/AND/LOMB/	/1%/	/N87838/001/ /JUL/28,/1982/	
AT	PHARMAFAIR	1%	N87838 001 JUL 28, 1982	

LOTION; TOPICAL

	/CORT-DOME/			
/AT/	/MILES/	/0.5%/	/N09895/003/	
/AT/		/1%/	/N09895/001/	
	∂ MILES	0.5%	N09895 003	
	∂	1%	N09895 001	

HYDROCORTISONE

LOTION; TOPICAL

	HYDROCORTISONE				
>DLT> /AT/	/THAMES/	/1%/	/N89024/001/ /FEB/12,/1986/		
>DLT> >ADD>	∂ THAMES	1%	N89024 001 FEB 12, 1986		

OINTMENT; TOPICAL

	HYDROCORTISONE			
AT	NMC	1%	N87796 001 OCT 13, 1982	
	/HYMAC/			
/AT/	/NMC/	/1%/	/N87796/001/ /OCT/13,/1982/	

SOLUTION; TOPICAL

	TEXACORT		
	GENDERM	2.5%‡	N81271 001 APR 17, 1992

TABLET; ORAL

	/HYCORTOLE/		
	/∂/VITARINE/	/20MG/	/N80642/002/
	HYDROCORTISONE		
	∂ EON LABS	20MG	N80642 002

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HEMSOL-HC		
AT	ABLE	1%‡	N81274 001 JUN 19, 1992

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

>DLT>	/CREAM;/TOPICAL/			
>DLT>	/NEO-CORTEF/			
>DLT>	/UPJOHN/	/1%;EQ/3.5MG/BASE/GM/	/N61049/001/	
>DLT>		/2.5%;EQ/3.5MG/BASE/GM/	/N61049/002/	
>ADD>	∂ UPJOHN	1%;EQ 3.5MG BASE/GM	N61049 001	
>ADD>	∂	2.5%;EQ 3.5MG BASE/GM	N61049 002	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OPHTHALMIC

	COR-OTICIN				
/AT/	/AKORN/	/1.5%;EQ 3.5MG BASE/ML/	/N60188/001/	> ADD >	
	AKORN	1.5%;EQ 3.5MG BASE/ML	N60188 001	> DLT >	
	/NEO-CORTEF;/				
/AT/	/UPJOHN/	/0.5%;EQ 3.5MG BASE/ML/	/N60612/002/		
/AT/		/1.5%;EQ 3.5MG BASE/ML/	/N60612/001/		
	ə UPJOHN	0.5%;EQ 3.5MG BASE/ML	N60612 002		
	ə	1.5%;EQ 3.5MG BASE/ML	N60612 001		

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

	/HYDROCORTISONE ACETATE/			
/AT/	/THAMES/	/1%;10%/	/N89472/001/	
			/JUN/13,/1988/	
	U-CORT			
AT	THAMES	1%;10%	N89472 001	
			JUN 13, 1988	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	HYDROCORTISONE SODIUM SUCCINATE		
/AP/	/ELKINS/SINN/	/EQ 100MG BASE/VIAL/	/N86619/001/
/AP/		/EQ 250MG BASE/VIAL/	/N87567/001/
/AP/		/EQ 500MG BASE/VIAL/	/N87568/001/
	ə ELKINS SINN	EQ 100MG BASE/VIAL	N86619 001
	ə	EQ 250MG BASE/VIAL	N87567 001
	ə	EQ 500MG BASE/VIAL	N87568 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	/HYDROFLUMETHIAZIDE/AND/RESERPINE/		
/B*/	/PHARM/BASICS/	/50MG;0.125MG/	/N88195/001/
			/OCT/26,/1983/
	ə PHARM BASICS	50MG;0.125MG	N88195 001
			OCT 26, 1983

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	PAREMYD		
	ALLERGAN	1%;0.25%	N19261 001

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

	PLAQUENIL		
	+ STERLING	200MG /EQ/155MG/BASE/	N09768 001 /N09768/001/

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL		
/AB/	/EON/LABS/	/10MG/	/N87246/002/
/AB/		/25MG/	/N85247/001/
/AB/		/50MG/	/N87245/001/
	ə EON LABS	10MG	N87246 002
	ə	25MG	N85247 001
	ə	50MG	N87245 001
/B*/	/PHARM/BASICS/	/10MG/	/N89121/001/ /MAR/20,/1986/
/B*/		/25MG/	/N89122/001/ /MAR/20,/1986/
/B*/		/50MG/	/N89123/001/ /MAR/20,/1986/
	ə PHARM BASICS	10MG	N89121 001 MAR 20, 1986
	ə	25MG	N89122 001 MAR 20, 1986
	ə	50MG	N89123 001 MAR 20, 1986

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HY-PAM		
AB	EON LABS	EQ 25MG HCL	N87479 001
/AB/	/VITARINE/	/EQ 25MG HCL/	/N87479/001/
	HYDROXYZINE PAMOATE		
AB	EON LABS	EQ 50MG HCL	N86183 001
/AB/	/VITARINE/	/EQ 50MG HCL/	/N86183/001/

IBUPROFEN

TABLET; ORAL

	IBUPROFEN		
/AB/	/BOOTS/	/600MG/	/N70556/001/ /JUN/14,/1985/
	ə BOOTS	600MG	N70556 001 JUN 14, 1985

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	LEMMON	400MG¤	N73343 001 JUN 30, 1992
AB		600MG¤	N73344 001 JUN 30, 1992
AB		800MG¤	N73345 001 JUN 30, 1992
> DLT > /AB/	/MEDICOPHARMA/	/400MG/	/N71644/001/ /FEB/01,/1988/
> DLT > /AB/	/SUPERPHARM/	/600MG/	/N70709/001/ /APR/25,/1986/
	ə SUPERPHARM	600MG	N70709 001 APR 25, 1986
> ADD > AB > ADD >	VINTAGE	400MG	N71644 001 FEB 01, 1988

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HCL

AB	EON LABS	10MG	N85200 001
AB		25MG	N84869 002
AB		50MG	N85133 001
/AB/	/VITARINE/	/25MG/	/N84869/002/
/AB/		/50MG/	/N85133/001/
/ə/		/10MG/	/N85200/001/

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

	ə EON LABS	25MG	N71711 001 JUL 05, 1988
	ə	50MG	N71712 001 JUL 05, 1988
> DLT > /AB/	/PIONEER/PHARMS/	/25MG/	/N70813/001/ /AUG/11,/1986/
> DLT > /AB/		/50MG/	/N70592/001/ /AUG/11,/1986/
> ADD >	ə PIONEER PHARMS	25MG	N70813 001 AUG 11, 1986
> ADD >	ə	50MG	N70592 001 AUG 11, 1986
/ə/	/VITARINE/	/25MG/	/N71711/001/ /JUL/05,/1988/
/ə/		/50MG/	/N71712/001/ /JUL/05,/1988/

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

/B*/	/EON/LABS/	/75MG/	/N71531/001/ /JUL/21,/1987/
	ə EON LABS	75MG	N71531 001 JUL 21, 1987

SUPPOSITORY; RECTAL

INDOCIN

AB	+ MERCK	50MG	N17814 001 AUG 13, 1984

INDOMETHEGAN

AB	G AND W	50MG¤	N73314 001 AUG 31, 1992

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE IMP

	1 MCI/ML	N19432 001 DEC 24, 1987
/MEDI/PHYSICS/	/1/MCI/ML/	/N19432/001/ /DEC/24,/1987/

IOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-250

SQUIBB	51%¤	N18735 007 JUL 06, 1992

IOPHENDYLATE

/INJECTABLE;/INJECTION/

/PANTOPAQUE/

/LAFAYETTE/	/100%/	/N05319/001/
ə ALCON	100%	N05319 001

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 300

MALLINCKRODT	64%¤	N19710 004 JAN 22, 1992

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 350
MALLINCKRODT 74%‡ N19710 005
JAN 22, 1992

IRON DEXTRAN

INJECTABLE; INJECTION
/IMFERON/
/AB/ /FISONS/ /EQ 50MG IRON/ML/ /N10787/002/
ə FISONS EQ 50MG IRON/ML N10787 002

IRON DEXTRAN
>DLT> /STERIS/ /EQ 50MG IRON/ML/ /N17441/001/
>ADD> BP STERIS EQ 50MG IRON/ML N17441 001
PROFERDEX
>DLT> /ə/FISONS/ /EQ/50MG/IRON/ML/ /N17807/001/
>ADD> BP LOTUS EQ 50MG IRON/ML N17807 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
/AN/ /ARMOUR/ /0.125%/ /N87938/001/ /NOV/15,/1982/
/AN/ /0.167%/ /N88470/001/ /MAR/14,/1984/
/AN/ /0.2%/ /N88471/001/ /MAR/14,/1984/
/AN/ /0.25%/ /N88472/001/ /MAR/14,/1984/
/0.062%/ /N87937/001/ /NOV/15,/1982/
AN ASTRA 0.125% N87938 001 NOV 15, 1982
0.062% N87937 001 NOV 15, 1982
ə 0.167% N88470 001 MAR 14, 1984
ə 0.2% N88471 001 MAR 14, 1984
ə 0.25% N88472 001 MAR 14, 1984

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE MCL
/AN/ /DEY/ /0.08%/ /N88187/001/ /DEC/03,/1982/
/AN/ /0.1%/ /N87389/001/
/AN/ /0.17%/ /N87390/001/
/AN/ /0.25%/ /N88188/001/ /DEC/03,/1982/
/AN/ /1%/ /N86763/001/
ə DEY 0.08% N88187 001 DEC 03, 1982
ə 0.1% N87389 001
ə 0.17% N87390 001
ə 0.25% N88188 001 DEC 03, 1982
ə 1% N86763 001
ISOETHARINE MCL S/F
AN DEY 0.17% N89819 001 NOV 22, 1988
/0.17%/ /N89819/001/ /NOV/22,/1988/

ISONIAZID

TABLET; ORAL
HYZYD
>DLT>/AA/ /MALLINCKRODT/ /100MG/ /N80134/003/
>DLT>/AA/ /300MG/ /N80134/004/
>ADD> AA WALLACE 100MG N80134 003
>ADD> AA 300MG N80134 004

/INH/
/AA/ /CIBA/ /100MG/ /N80935/001/
ə CIBA 300MG N80935 001

ISONIAZID
AA EON LABS 100MG N08678 002
AA 300MG N08678 003
/AA/ /LILLY/ /100MG/ /N08499/002/
/AA/ /300MG/ /N08499/003/
ə LILLY 100MG N08499 002
ə 300MG N08499 003
/AA/ /VITARINE/ /100MG/ /N08678/002/
/AA/ /300MG/ /N08678/003/

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION
ISOPROTERENOL HCL

/AN/	/DEY/	/0.5%/	/N86764/001/ /JAN/04,/1982/
	ə DEY	0.5%	N86764 001 JAN 04, 1982

ISOSORBIDE DINITRATE

TABLET; ORAL
ISORDIL

> ADD >	AB	WYETH AYERST	40MG	N12093 001 JUL 29, 1988
> ADD >		SORBITRATE		
> ADD >	AB	ICI	20MG	N86405 002 AUG 21, 1990
> ADD >	AB		30MG	N88124 001 AUG 21, 1990
> ADD >	AB		40MG	N88125 001 AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET; ORAL
ISMO

+	WYETH	20MG	N19091 001 DEC 30, 1991
		/20MG/	/N19091/001/ /DEC/30,/1991/

ITRACONAZOLE

CAPSULE; ORAL
SPORANOX

+	JANSSEN	100MG¤	N20083 001 SEP 11, 1992

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN SULFATE

	AP	LOCH	EQ 75MG BASE/2ML¤	N63021 001 JUL 31, 1992
	AP		EQ 500MG BASE/2ML¤	N63022 001 JUL 31, 1992
	AP		EQ 1GM BASE/3ML¤	N63025 001 JUL 31, 1992
> DLT >	/AP/	/LYPHOMED/	/EQ 75MG BASE/2ML/	/N62504/001/ /APR/05,/1984/
> DLT >	/AP/		/EQ 500MG BASE/2ML/	/N62504/002/ /APR/05,/1984/
> DLT >	/AP/		/EQ 1GM BASE/3ML/	/N62504/003/ /APR/05,/1984/
> ADD >		ə LYPHOMED	EQ 75MG BASE/2ML	N62504 001 APR 05, 1984
> ADD >		ə	EQ 500MG BASE/2ML	N62504 002 APR 05, 1984
> ADD >		ə	EQ 1GM BASE/3ML	N62504 003 APR 05, 1984

KETOROLAC TROMETHAMINE

> ADD > SOLUTION/DROPS; OPHTHALMIC
> ADD > ACULAR

> ADD >	SYNTEX	0.5%¤	N19700 001 NOV 09, 1992

TABLET; ORAL
TORADOL

+	SYNTEX	10MG	N19645 001 DEC 20, 1991
		/10MG/	/N19645/001/ /DEC/20,/1991/

LACTULOSE

SYRUP; ORAL
LACTULOSE

AA	PACO	10GM/15ML¤	N73160 001 AUG 25, 1992
AA	ROXANE	10GM/15ML¤	N73591 001 MAY 29, 1992
AA	UDL	10GM/15ML¤	N74138 001 SEP 30, 1992

LACTULOSE

SYRUP; ORAL, RECTAL
LACTULOSE

AA	PACO	10GM/15ML¤	N72029 001 AUG 25, 1992
AA	ROXANE	10GM/15ML¤	N73590 001 MAY 29, 1992

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

> DLT >	/AP/ /ABIC/	/EQ 3MG BASE/ML/	/N89352/001/ /JUN/01,/1988/
> DLT >	/AP/	/EQ 50MG BASE/VIAL/	/N89353/001/ /JUN/01,/1988/
> ADD >	ə ABIC	EQ 3MG BASE/ML	N89352 001 JUN 01, 1988
> ADD >	ə	EQ 50MG BASE/VIAL	N89353 001 JUN 01, 1988
> ADD >	/AP/ /LYPHOMED/	/EQ 50MG BASE/VIAL/	/N88939/001/ /DEC/01,/1986/
	ə LYPHOMED	EQ 50MG BASE/VIAL	N88939 001 DEC 01, 1986

LEVOCARNITINE

SOLUTION; ORAL
CARNITOR

AA	SIGMA TAU	1GM/10ML	N19257 001 APR 10, 1986
/AA/	/VITACARN/ /MCGAW/	/1GM/10ML/	/N19257/001/ /APR/10,/1986/

LEVODOPA

CAPSULE; ORAL
DOPAR

/+//P/AND/G/		/500MG/ /100MG/ /250MG/	/N16913/002/ /N16913/003/ /N16913/001/
+	ROBERTS	500MG 100MG 250MG	N16913 002 N16913 003 N16913 001

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN

+	ROCHE	2MG	N08720 001 DEC 19, 1991
		/2MG/	/N08720/001/ /DEC/19,/1991/

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL

	/INTL/MEDICATION/	/1GM/VIAL/	/N18543/001/
	ə INTL MEDICATION	1GM/VIAL	N18543 001
		/2GM/VIAL/	/N18543/002/
	ə	2GM/VIAL	N18543 002

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	200MG/100ML¤	N19830 002 APR 08, 1992

LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	400MG/100ML¤	N19830 003 APR 08, 1992

LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	800MG/100ML¤	N19830 004 APR 08, 1992

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

/B*/	/PHARM/BASICS/	/300MG/	/N72542/001/ /FEB/01,/1989/
	ə PHARM BASICS	300MG	N72542 001 FEB 01, 1989

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL
MAXAQUIN

+	SEARLE	EQ 400MG BASE¤	N20013 001 FEB 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HCL

AB	GENEVA	2MG¤	N72993 001

LOPERAMIDE HCL
AB GENEVA 2MG* N72993 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HCL
AB LEMMON 2MG* N73192 001 APR 30, 1992

LORACARBEF

CAPSULE; ORAL
LORABID
+ LILLY 200MG N50668 001 DEC 31, 1991
/200MG/ /N50668/001/ /DEC/31,/1991/

POWDER FOR RECONSTITUTION; ORAL
LORABID
+ LILLY 200MG/5ML N50667 002 DEC 31, 1991
/200MG/5ML/ /N50667/002/ /DEC/31,/1991/

LORAZEPAM

TABLET; ORAL
LORAZEPAM
/B*/ /PHARM/BASICS/ /1MG/ /N70539/001/ /DEC/22,/1986/
/B*/ /2MG/ /N70540/001/ /DEC/22,/1986/
∂ PHARM BASICS 1MG N70539 001 DEC 22, 1986
∂ 2MG N70540 001 DEC 22, 1986

MANNITOL

INJECTABLE; INJECTION
MANNITOL 25%
/AP/ /LYPHOMED/ /12.5GM/50ML/ /N86754/001/
∂ LYPHOMED 12.5GM/50ML N86754 001

MASOPROCOL

CREAM; TOPICAL
ACTINEX
+ CHEMEX 10%* N19940 001 SEP 04, 1992

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM
/B*/ /PHARM/BASICS/ /EQ/50MG/BASE/ /N71007/001/ /MAR/25,/1988/
/B*/ /EQ/100MG/BASE/ /N71008/001/ /MAR/25,/1988/
∂ PHARM BASICS EQ 50MG BASE N71007 001 MAR 25, 1988
∂ EQ 100MG BASE N71008 001 MAR 25, 1988

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
DEPO-PROVERA
UPJOHN 150MG/ML* N20246 001 OCT 29, 1992

TABLET; ORAL
CYCRIN
AB WYETH AYERST 2.5MG* N81239 001 OCT 30, 1992
AB 5MG* N81240 001 OCT 30, 1992
PROVERA
AB UPJOHN 2.5MG N11839 001
AB 5MG N11839 003

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID
∂ EON LABS 250MG N72179 001 APR 21, 1988
/∂/VITARINE/ /250MG/ /N72179/001/ /APR/21,/1988/

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

/B*/	/PHARM/BASICS/	/20MG/	/N70646/001/ /OCT/02,/1987/
/B*/		/40MG/	/N70647/001/ /OCT/02,/1987/
∂	PHARM BASICS	20MG	N70646 001 OCT 02, 1987
∂		40MG	N70647 001 OCT 02, 1987

> ADD > MELPHALAN HYDROCHLORIDE

> ADD > INJECTABLE; INJECTION
> ADD > ALKERAN

> ADD >	BURROUGHS WELLCOME	EQ 50MG BASE/VIAL¤	N20207 001 NOV 18, 1992

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

AP	ABBOTT	10MG/ML	N88432 001 AUG 16, 1984
/AP/	/PARKE/DAVIS/	/50MG/ML/	/N80364/002/
/AP/		/75MG/ML/	/N80364/003/
/AP/		/100MG/ML/	/N80364/001/
∂	PARKE DAVIS	50MG/ML	N80364 002
∂		75MG/ML	N80364 003
∂		100MG/ML	N80364 001
AP	STERIS	10MG/ML¤	N73443 001 MAR 17, 1992
AP		50MG/ML¤	N73444 001 MAR 17, 1992
AP		100MG/ML¤	N73445 001 MAR 17, 1992

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
/POLOCAINE/

/AP/	/ASTRA/	/1%/	/N89406/001/ /DEC/01,/1986/
/AP/		/1.5%/	/N89408/001/ /DEC/01,/1986/
/AP/		/2%/	/N89409/001/ /DEC/01,/1986/

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
POLOCAINE-MPF

AP	ASTRA	1%	N89406 001 DEC 01, 1986
AP		1.5%	N89408 001 DEC 01, 1986
AP		2%	N89409 001 DEC 01, 1986

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

∂	ELKINS SINN	200MG	N15426 002
∂		400MG	N15426 001
AA	EON LABS	200MG	N14547 002
AA		400MG	N14547 001
/AA/	/HEATHER/	/600MG/	/N84329/001/
∂	HEATHER	600MG	N84329 001
/AA/	/ICN/	/200MG/	/N15139/006/
/AA/		/400MG/	/N15139/005/
∂	ICN	200MG	N15139 006
∂		400MG	N15139 005
/AA/	/PARKE/DAVIS/	/200MG/	/N84744/001/
/AA/		/400MG/	/N84744/002/
∂	PARKE DAVIS	200MG	N84744 001
∂		400MG	N84744 002
/∂/	/QUANTUM/PHARMICS/	/200MG/	/N15426/002/
/∂/		/400MG/	/N15426/001/
/AA/	/VITARINE/	/200MG/	/N14547/002/
/AA/		/400MG/	/N14547/001/
/AA/	/ZENITH/	/200MG/	/N15438/001/
/AA/		/400MG/	/N15438/002/
∂	ZENITH	200MG	N15438 001
∂		400MG	N15438 002

MESALAMINE

TABLET, DELAYED RELEASE; ORAL
ASACOL

+	P AND G	400MG¤	N19651 001 JAN 31, 1992

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	METAPROTERENOL SULFATE		
/AN/	/ARMOUR/	/0.4%/	/N71275/001/ /JUL/27,/1988/
/AN/		/0.6%/	/N71018/001/ /JUL/27,/1988/
AN	ASTRA	0.4%	N71275 001 JUL 27, 1988
AN		0.6%	N71018 001 JUL 27, 1988
	/DEY/	/0.33%/	/N71806/001/ /AUG/05,/1988/
	∂ DEY	0.33%	N71806 001 AUG 05, 1988
	PROMETA		
AN	MURO	5%¤	N73340 001 MAR 30, 1992

SYRUP; ORAL

	METAPROTERENOL SULFATE		
AA	BIOCRAFT	10MG/5ML¤	N72761 001 FEB 27, 1992
AA	SILARX	10MG/5ML¤	N73632 001 JUL 22, 1992

TABLET; ORAL

	METAPROTERENOL SULFATE		
/B*/	/PHARM/BASICS/	/10MG/	/N71013/001/ /JAN/25,/1988/
/B*/		/20MG/	/N71014/001/ /JAN/25,/1988/
	∂ PHARM BASICS	10MG	N71013 001 JAN 25, 1988
	∂	20MG	N71014 001 JAN 25, 1988

METHADONE HYDROCHLORIDE

TABLET, DISPERSIBLE; ORAL

	METHADONE		
	∂ EON LABS	2.5MG	N17108 001
	∂	5MG	N17108 002
	∂	10MG	N17108 003
	∂	40MG	N17108 004
	/∂/VITARINE/	/2.5MG/	/N17108/001/
	/∂/	/5MG/	/N17108/002/
	/∂/	/10MG/	/N17108/003/
	/∂/	/40MG/	/N17108/004/

METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL		
AA	EON LABS	500MG	N87283 001
AA		750MG	N87282 001
/AA/	/HEATHER/	/500MG/	/N84675/001/
/AA/		/750MG/	/N84924/001/
	∂ HEATHER	500MG	N84675 001
	∂	750MG	N84924 001
/AA/	/VITARINE/	/500MG/	/N87283/001/
/AA/		/750MG/	/N87282/001/

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	ABITREXATE		
>DLT>/AP/	/ABIC/	/EQ 25MG BASE/ML/	/N89161/001/ /MAR/10,/1987/
>DLT>/AP/		/EQ 50MG BASE/VIAL/	/N89354/001/ /JUL/17,/1987/
>DLT>/AP/		/EQ 100MG BASE/VIAL/	/N89355/001/ /JUL/17,/1987/
>DLT>/AP/		/EQ 250MG BASE/VIAL/	/N89356/001/ /JUL/17,/1987/
>ADD>	∂ ABIC	EQ 25MG BASE/ML	N89161 001 MAR 10, 1987
>ADD>	∂	EQ 50MG BASE/VIAL	N89354 001 JUL 17, 1987
>ADD>	∂	EQ 100MG BASE/VIAL	N89355 001 JUL 17, 1987
>ADD>	∂	EQ 250MG BASE/VIAL	N89356 001 JUL 17, 1987

TABLET; ORAL

	METHOTREXATE		
AB	MYLAN	EQ 2.5MG BASE¤	N81235 001 MAY 15, 1992

METHOXYFLURANE

LIQUID; INHALATION

	PENTHRANE		
	ABBOTT	99.9%	N13056 001
/SOLUTION;/INHALATION/			
	/PENTHRANE/		
	/ABBOTT/	/99.9%/	/N13056/001/

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

/B*/	/PHARM/BASICS/	/5MG/	/N88745/001/ /MAR/21,/1985/		
	∂ PHARM BASICS	5MG	N88745 001 MAR 21, 1985		

METHYLDOPA

TABLET; ORAL
METHYLDOPA

/AB/	/PARKE/DAVIS/	/125MG/	/N70331/001/ /APR/15,/1986/		
/AB/		/250MG/	/N70332/001/ /APR/15,/1986/		
/AB/		/500MG/	/N70333/001/ /APR/15,/1986/		
	∂ PARKE DAVIS	125MG	N70331 001 APR 15, 1986		
	∂	250MG	N70332 001 APR 15, 1986		
	∂	500MG	N70333 001 APR 15, 1986		

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

	∂ EON LABS	4MG	N87341 001		
/∂/	/VITARINE/	/4MG/	/N87341/001/		

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE

/AP/	/ELKINS/SINN/	/EQ 125MG BASE/VIAL/	/N86906/002/		
/AP/		/EQ 500MG BASE/VIAL/	/N86906/003/		
/AP/		/EQ 1GM BASE/VIAL/	/N86906/004/		
	∂ ELKINS SINN	EQ 125MG BASE/VIAL	N86906 002		
	∂	EQ 500MG BASE/VIAL	N86906 003		
	∂	EQ 1GM BASE/VIAL	N86906 004		

METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/ELKINS/SINN/	/EQ 40MG BASE/VIAL/	/N86906/001/		
	∂ ELKINS SINN	EQ 40MG BASE/VIAL	N86906 001		

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

	GENSIA	EQ 125MG BASE/VIAL¤	> ADD > > ADD >	AP	N81266 001 NOV 30, 1992
		EQ 500MG BASE/VIAL¤	> ADD > > ADD >	AP	N81267 001 NOV 30, 1992
		EQ 1GM BASE/VIAL¤	> ADD > > ADD >	AP	N81268 001 NOV 30, 1992

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL
METOCLOPRAMIDE INTENSOL

ROXANE	EQ 10MG BASE/ML¤		N72995 001 JAN 30, 1992

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	CETUS BEN VENUE	EQ 10MG BASE/2ML¤	N72155 001 MAR 30, 1992
AP		EQ 10MG BASE/2ML¤	N72244 001 MAR 30, 1992
AP		EQ 10MG BASE/2ML¤	N72247 001 MAY 18, 1992

SOLUTION; ORAL
METOCLOPRAMIDE HCL

AA	SILARX	EQ 5MG BASE/5ML¤	N73680 001 OCT 27, 1992

TABLET; ORAL
METOCLOPRAMIDE HCL

/B*/	/INTERPHARM/	/EQ/10MG/BASE/	/N71213/001/ /SEP/24,/1986/
	∂ INTERPHARM	EQ 10MG BASE	N71213 001 SEP 24, 1986
/B*/	/PHARM/BASICS/	/EQ/10MG/BASE/	/N70339/001/ /JUL/29,/1985/
	∂ PHARM BASICS	EQ 10MG BASE	N70339 001 JUL 29, 1985

METOLAZONE

TABLET; ORAL
ZAROXOLYN

AB		SCHIAPPARELLI SEARLE	2.5MG	N18535 001
AB			5MG	N18535 002
AB			10MG	N18535 003
AB	+	FISONS	10MG	N17386 003
AB	+		2.5MG	N17386 001
AB	+		5MG	N17386 002

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
TOPROL XL

	+	HASSLE	EQ 50MG TARTRATE¤	N19962 001 JAN 10, 1992
	+		EQ 100MG TARTRATE¤	N19962 002 JAN 10, 1992
	+		EQ 200MG TARTRATE¤	N19962 003 JAN 10, 1992

METRONIDAZOLE

GEL; VAGINAL
METROGEL

	+	CURATEK	0.75%¤	N20208 001 AUG 17, 1992

INJECTABLE; INJECTION
METRONIDAZOLE

AP		LYPHOMED	500MG/100ML	N70071 001 DEC 03, 1984

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

AB		EON LABS	250MG	N18620 001 MAR 04, 1982
AB			500MG	N18620 002 JUN 02, 1983
AB		VITARINE	250MG	N18620 001 MAR 04, 1982
AB			500MG	N18620 002 JUN 02, 1983

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
FLAGYL I.V.

AP		SCHIAPPARELLI SEARLE	EQ 500MG BASE/VIAL	N18353 001

METRONIDAZOLE HCL

AP		LYPHOMED	EQ 500MG BASE/VIAL	N70295 001 OCT 15, 1985

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

AB		BIOCRAFT	EQ 50MG BASE¤	N63011 001 MAR 02, 1992
AB			EQ 100MG BASE¤	N63009 001 MAR 02, 1992

SUSPENSION; ORAL
MINOCIN

	+	LEDERLE	EQ 50MG BASE/5ML	N50445 001

SYRUP; ORAL
MINOCIN

	+	LEDERLE	EQ 50MG BASE/5ML	N50445 001

MINOXIDIL

TABLET; ORAL
MINOXIDIL

/B*/	/PHARM/BASICS/	/2.5MG/	/N71537/001/ /DEC/16,/1988/
	∂ PHARM BASICS	2.5MG	N71537 001 DEC 16, 1988
/AB/	/ROYCE/	/2.5MG/	/N71799/001/ /NOV/10,/1987/
/AB/		/10MG/	/N71796/001/ /NOV/10,/1987/
	∂ ROYCE	2.5MG	N71799 001 NOV 10, 1987
	∂	10MG	N71796 001 NOV 10, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACRON

BURROUGHS WELLCOME	EQ 2MG BASE/ML¤	N20098 001 JAN 22, 1992

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

BURROUGHS WELLCOME	EQ 0.5MG BASE/ML¤	N20098 002 JAN 22, 1992
	EQ 50MG BASE/100ML¤	N20098 003 JAN 22, 1992

MONOBENZONE

CREAM; TOPICAL
BENOQUIN

/ELDER/	/20%/	/N08173/003/
ICN	20%	N08173 003

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE

AP	ABBOTT	0.5MG/ML¤	N19917 001 OCT 30, 1992
AP		0.5MG/ML¤	N73509 001 SEP 30, 1992
AP		1MG/ML¤	N19916 001 OCT 30, 1992
AP		1MG/ML¤	N73510 001 SEP 30, 1992

NABUMETONE

TABLET; ORAL
RELAFEN

+	SMITHKLINE BEECHAM	750MG	N19583 002 DEC 24, 1991
		/750MG/	/N19583/002/ /DEC/24,/1991/

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL

SYNTEX	EQ 0.2MG BASE/INH¤	N20109 001 FEB 26, 1992

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
/NALBUPHINE/

/AP/	/LYPHOMED/	/10MG/ML/	/N70751/001/ /JUL/02,/1986/
/AP/		/20MG/ML/	/N70752/001/ /JUL/02,/1986/
	∂ LYPHOMED	10MG/ML	N70751 001 JUL 02, 1986
	∂	20MG/ML	N70752 001 JUL 02, 1986

NAPROXEN

TABLET; ORAL
NAPROSYN

AB	SYNTEX	250MG	N17581 002
AB		375MG	N17581 003
AB		500MG	N17581 004 APR 15, 1982

NAPROXEN

AB	HAMILTON	250MG¤	N74110 001 OCT 30, 1992
AB		375MG¤	N74110 002 OCT 30, 1992
AB		500MG¤	N74110 003 OCT 30, 1992

NEOMYCIN SULFATE

NICOTINE

NEOMYCIN SULFATE

TABLET; ORAL
NEOMYCIN SULFATE

AA	EON LABS	EQ 350MG BASE	N61586 001
/AA/	/VITARINE/	/EQ 350MG BASE/	/N61586/001/

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

/SUSPENSION/DROPS;/OPHTHALMIC/
/NEO-DELTA-CORTEF/

/UPJOHN/	/EQ/3.5MG/BASE/ML;0.25%/	/N61037/001/
ə UPJOHN	EQ 3.5MG BASE/ML;0.25%	N61037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

/OINTMENT;/OPHTHALMIC/
/NEO-HYDELTRASOL/

/MSD/	/EQ/3.5MG/BASE/GM;/ /EQ/0.25%/PHOSPHATE/	/N50378/001/
ə MSD	EQ 3.5MG BASE/GM; EQ 0.25% PHOSPHATE	N50378 001

NIACIN

TABLET; ORAL
NIACIN

AA	WOCKHARDT	500MG¤	N81134 001 APR 28, 1992

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDENE SR

+	SYNTEX	30MG¤	N20005 001 FEB 21, 1992
+		45MG¤	N20005 002 FEB 21, 1992
+		60MG¤	N20005 003 FEB 21, 1992

INJECTABLE; INJECTION
CARDENE

DUPONT MERCK	2.5MG/ML¤	N19734 001 JAN 30, 1992

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
NICODERM

/BC/	/MARION/MERRELL/DOW/	/7MG/24HR/	/N20165/001/ /NOV/07,/1991/
BC +	MARION MERRELL DOW	7MG/24HR	N20165 001 NOV 07, 1991
/BC/		/14MG/24HR/	/N20165/002/ /NOV/07,/1991/
BC +		14MG/24HR	N20165 002 NOV 07, 1991
/BC/		/21MG/24HR/	/N20165/003/ /NOV/07,/1991/
BC +		21MG/24HR	N20165 003 NOV 07, 1991

NICOTROL

+	KABI	5MG/16HR¤	N20150 001 APR 22, 1992
+		10MG/16HR¤	N20150 002 APR 22, 1992
+		15MG/16HR¤	N20150 003 APR 22, 1992

PROSTEP

+	ELAN	11MG/24HR¤	N19983 001 JAN 28, 1992
+		22MG/24HR¤	N19983 002 JAN 28, 1992

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE

MERRELL DOW	EQ 2MG BASE	N18612 001 JAN 13, 1984

NICORETTE DS

+	MERRELL DOW	EQ 4MG BASE¤	N20066 001 JUN 08, 1992

/GUM;/CHEWING;/ORAL/
/NICORETTE/

/+//MERRELL/DOW/	/EQ/2MG/BASE/	/N18612/001/ /JAN/13,/1984/

NICORETTE DS

/+//MERRELL/DOW/	/4MG¤/	/N20066/001/ /JUN/08,/1992/

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	NOVOPHARM	10MG¤	N72651 001 FEB 19, 1992
AB	SCHERER	20MG¤	N74045 001 APR 30, 1992

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

ə EON LABS	50MG	N80043 001
ə	100MG	N80043 002
/ə/VITARINE/	/50MG/	/N80043/001/
/ə/	/100MG/	/N80043/002/

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE, EXTENDED RELEASE; ORAL

MACROBID

+ P AND G	75MG;25MG	N20064 001 DEC 24, 1991
	/75MG;25MG/	/N20064/001/ /DEC/24,/1991/

NITROFURAZONE

DRESSING; TOPICAL

FURACIN

/AT/	/ROBERTS/	/0.2%/	/N05795/001/

/NITROFURAZONE/

/AT/	/THAMES/	/0.2%/	/N86156/001/

OINTMENT; TOPICAL

FURACIN

AT	ROBERTS	0.2%	N05795 001

NITROFURAZONE

AT	THAMES	0.2%	N86156 001

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN

/AP/	/LUITPOLD/	/5MG/ML/	/N71492/001/ /MAY/24,/1988/
	ə LUITPOLD	5MG/ML	N71492 001 MAY 24, 1988

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HCL

AB	DANBURY	EQ 10MG BASE¤	N73553 001 MAR 30, 1992
AB		EQ 25MG BASE¤	N73554 001 MAR 30, 1992
AB		EQ 50MG BASE¤	N73555 001 MAR 30, 1992
AB		EQ 75MG BASE¤	N73556 001 MAR 30, 1992

PAMELOR

AB	SANDOZ	EQ 10MG BASE	N18013 001
AB		EQ 25MG BASE	N18013 002
AB		EQ 50MG BASE	N18013 004
AB +		EQ 75MG BASE	N18013 003
/BD/		/EQ/10MG/BASE/	/N18013/001/
/BD/		/EQ/25MG/BASE/	/N18013/002/

NYSTATIN

/SUPPOSITORY;/VAGINAL/

/NYSERT/

/P/AND/G/	/100,000/UNITS/	/N50478/001/
ə P AND G	100,000 UNITS	N50478 001

TABLET; ORAL

NYSTATIN

/AA/	/CHELSEA/	/500,000 UNITS/	/N62402/001/ /DEC/16,/1982/
	ə CHELSEA	500,000 UNITS	N62402 001 DEC 16, 1982
AA	EON LABS	500,000 UNITS	N62065 001
/AA/	/VITARINE/	/500,000 UNITS/	/N62065/001/

TABLET; VAGINAL

NYSTATIN

ə EON LABS	100,000 UNITS	N61965 001

TABLET; VAGINAL
NYSTATIN
∂ EON LABS 100,000 UNITS N61965 001

NYSTATIN

TABLET; VAGINAL
NYSTATIN
/∂/ /VITARINE/ /100,000/UNITS/ /N61965/001/

NYSTATIN: TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
> DLT > /DERMACOMB/
> DLT > /AT/ /TARO/ /100,000 UNITS/GM;0.1%/ /N62364/001/
> DLT > /DEC/22,/1987/

NYSTATIN AND TRIAMCINOLONE ACETONIDE
/AT/ /CLAY/PARK/ /100,000 UNITS/GM;0.1%/ /N62186/002/
/JUN/06,/1985/

B* CLAY PARK 100,000 UNITS/GM;0.1% N62186 002
JUN 06, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE
> ADD > AT TARO 100,000 UNITS/GM;0.1% N62364 001
> ADD > DEC 22, 1987

OFLOXACIN

INJECTABLE; INJECTION
FLOXIN
JOHNSON RW 20MG/ML¤ N20087 002
MAR 31, 1992
40MG/ML¤ N20087 003
MAR 31, 1992

FLOXIN IN DEXTROSE 5%
JOHNSON RW 400MG/100ML¤ N20087 001
MAR 31, 1992

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
JOHNSON RW 4MG/ML¤ N20087 004
MAR 31, 1992
400MG/100ML¤ N20087 005
MAR 31, 1992

OXAPROZIN

TABLET; ORAL
DAYPRO
+ SEARLE 600MG¤ N18841 004
OCT 29, 1992

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM
/B*/ /CHELSEA/ /10MG/ /N71661/001/
/MAR/02,/1988/
/B*/ /15MG/ /N71662/001/
/MAR/02,/1988/
/B*/ /30MG/ /N71663/001/
/MAR/02,/1988/

OXICONAZOLE NITRATE

LOTION; TOPICAL
OXISTAT
+ GLAXO EQ 1% BASE¤ N20209 001
SEP 30, 1992

OXYBUTYNIN CHLORIDE

TABLET; ORAL
OXYBUTYNIN CHLORIDE
/B*/ /PHARM/BASICS/ /5MG/ /N70746/001/
/MAR/10,/1988/
∂ PHARM BASICS 5MG N70746 001
MAR 10, 1988

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM
/AP/ /PARKE/DAVIS/ /1,000,000 UNITS/VIAL/ /N62003/001/
/AP/ /5,000,000 UNITS/VIAL/ /N62003/002/
∂ PARKE DAVIS 1,000,000 UNITS/VIAL N62003 001
∂ 5,000,000 UNITS/VIAL N62003 002

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
/PENAPAR-VK/
/AA/ /PARKE/DAVIS/ /EQ 125MG BASE/5ML/ /N62002/001/
/AA/ /EQ 250MG BASE/5ML/ /N62002/002/
∂ PARKE DAVIS EQ 125MG BASE/5ML N62002 001
∂ EQ 250MG BASE/5ML N62002 002

PENICILLIN V POTASSIUM

TABLET; ORAL
PENAPAR-VK

AB	PARKE/DAVIS	EQ 250MG BASE	N62001 001
AB		EQ 500MG BASE	N62001 002
∂	PARKE DAVIS	EQ 250MG BASE	N62001 001
∂		EQ 500MG BASE	N62001 002

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
PENTAM 300

AP	FUJISAWA	300MG/VIAL	N19264 001 OCT 16, 1984

PENTAMIDINE ISETHIONATE

AP	ABBOTT	300MG/VIAL	N73479 001 JUN 30, 1992

PERPHENAZINE

TABLET; ORAL
PERPHENAZINE

B*	CHELSEA	8MG	N89700 001 DEC 23, 1983

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE

AA	EON LABS	35MG	N85633 001
AA		35MG	N85694 001
AA		35MG	N85695 001
AA		35MG	N85702 001
AA	VITARINE	35MG	N85633 001
AA		35MG	N85694 001
AA		35MG	N85695 001
AA		35MG	N85702 001

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

BC	EON LABS	105MG	N18074 001
BC	VITARINE	105MG	N18074 001

TABLET; ORAL
ALPHAZINE

∂	EON LABS	35MG	N85034 001
∂	VITARINE	35MG	N85034 001

OBEZINE

AA	PHARM/BASICS	35MG	N83805 001
AA		35MG	N84398 001
AA		35MG	N84399 001

PHENDIMETRAZINE TARTRATE

AA	EON LABS	35MG	N85402 001
AA		35MG	N85497 001
AA		35MG	N85588 001
AA		35MG	N85830 001
∂		35MG	N85830 001

PHENDIMETRAZINE TARTRATE

AA	PHARM BASICS	35MG	N84399 001
∂		35MG	N83805 001
∂		35MG	N84398 001

PHENDIMETRAZINE TARTRATE

AA	VITARINE	35MG	N85402 001
AA		35MG	N85497 001
AA		35MG	N85588 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	EON LABS	15MG	N87301 001
AA		30MG	N86945 001 JUL 20, 1983
AA		30MG	N87190 001
AA		30MG	N87208 001
AA		30MG	N87223 001
AA	VITARINE	15MG	N87301 001
AA		30MG	N86945 001 JUL 20, 1983
AA		30MG	N87190 001
AA		30MG	N87208 001
AA		30MG	N87223 001

TABLET; ORAL
PHENTERMINE HCL

∂	EON LABS	8MG	N85671 001
∂		8MG	N85689 001
∂	VITARINE	8MG	N85671 001

PHENYLBUTAZONE

CAPSULE; ORAL

/AZOLID/				
/AB/	/RHONE/POULENC/RORER//100MG/		/N87260/001/	
	@ RHONE POULENC RORER	100MG	N87260 001	

TABLET; ORAL

/AZOLID/				
/AB/	/RHONE/POULENC/RORER//100MG/		/N87091/001/	
	@ RHONE POULENC RORER	100MG	N87091 001	

PHENYTOIN

SUSPENSION; ORAL

	DILANTIN-125			
AB	+ PARKE DAVIS	125MG/5ML	N08762 001	
	PHENYTOIN			
AB	BARRE	125MG/5ML¤	N89892 001	SEP 25, 1992

PHENYTOIN SODIUM

INJECTABLE; INJECTION

		PHENYTOIN SODIUM			
> ADD >	AP	MARSAM	50MG/ML¤	N89779 001	NOV 27, 1992
> ADD >					

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL

/PHENYTOIN/SODIUM/				
/BX/	/CHELSEA/	/100MG/	/N85894/001/	
	@ CHELSEA	100MG	N85894 001	

PINDOLOL

TABLET; ORAL

	PINDOLOL			
AB	GENPHARM	5MG¤	N74013 001	SEP 24, 1992
AB		10MG¤	N74018 001	SEP 24, 1992
AB	MYLAN	5MG¤	N74019 001	SEP 03, 1992
AB		10MG¤	N74019 002	SEP 03, 1992

PINDOLOL

TABLET; ORAL

	VISKEN			
AB	SANDOZ	5MG	N18285 001	SEP 03, 1982
AB	+	10MG	N18285 002	SEP 03, 1982

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

		MAXAIR			
> ADD >		3M	EQ 0.2MG BASE/INH¤	N20014 001	NOV 30, 1992
> ADD >					

PIROXICAM

CAPSULE; ORAL

	FELDENE			
AB	PFIZER	10MG	N18147 002	APR 06, 1982
AB	+	20MG	N18147 003	APR 06, 1982
	PIROXICAM			
AB	COPLEY	10MG¤	N74103 001	AUG 28, 1992
AB		20MG¤	N74103 002	AUG 28, 1992
AB	GENPHARM	10MG¤	N74043 001	SEP 22, 1992
AB		20MG¤	N74043 002	SEP 22, 1992
AB	MYLAN	10MG¤	N74102 001	JUL 31, 1992
AB		20MG¤	N74102 002	JUL 31, 1992
AB	SCHIAPPARELLI SEARLE	10MG¤	N74036 001	MAY 29, 1992
AB		20MG¤	N74036 002	MAY 29, 1992

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	CO-LAV			
AA	COPLEY	240GM/BOT;2.98GM/BOT;6.72GM/BOT; 5.84GM/BOT;22.72GM/BOT¤	N73428 001	JAN 28, 1992

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

GO-EVAC

AA	COPLEY	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT¤	N73433 001 APR 28, 1992

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

AB	ADRIA	8MEQ¤	N73398 001 JAN 28, 1992

MICRO-K

AB	ROBINS	8MEQ	N18238 001

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

> ADD >	AP	ABBOTT	745MG/100ML¤	N20161 001 NOV 30, 1992
> ADD >	AP		14.9MG/ML¤	N20161 005 NOV 30, 1992
> ADD >	AP	BAXTER	746MG/100ML	N19904 005 DEC 17, 1990
> ADD >	AP		14.9MG/ML	N19904 001 DEC 26, 1989

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

> ADD >	AP	ABBOTT	1.49GM/100ML¤	N20161 002 NOV 30, 1992
> ADD >	AP	BAXTER	1.49GM/100ML	N19904 006 DEC 17, 1990

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

AB	UPSHER SMITH	8MEQ	N19123 001 APR 17, 1986
/BC/		/8MEQ/	/N19123/001/ /APR/17,/1986/

KLOTRIX

BC	APOTHECON	10MEQ	N17850 001
/BC/	/MEAD/JOHNSON/	/10MEQ/	/N17850/001/

PRAZEPAM

CAPSULE; ORAL

CENTRAX

/AB/	/PARKE/DAVIS/	/5MG/	/N18144/001/
/AB/	/+/	/10MG/	/N18144/002/
	+ PARKE DAVIS	10MG	N18144 002
		5MG	N18144 001

/PRAZEPAM;/

/B*/	/PHARM/BASICS/	/5MG/	/N70427/001/ /NOV/06,/1987/
/B*/		/10MG/	/N70428/001/ /NOV/06,/1987/
	∂ PHARM BASICS	5MG	N70427 001 NOV 06, 1987
	∂	10MG	N70428 001 NOV 06, 1987

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

/AB/	/PFIZER/	/EQ 2MG BASE/	/N17442/003/
AB	+ PFIZER	EQ 2MG BASE	N17442 003
/AB/	/+/	/EQ 5MG BASE/	/N17442/001/
AB		EQ 5MG BASE	N17442 001

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

	+ PFIZER	2.5MG¤	N19775 001 JAN 29, 1992
	+	5MG¤	N19775 002 JAN 29, 1992

PREDNISOLONE

TABLET; ORAL

/DELTA-CORTEF/

/BX/	/+/ /UPJOHN/	/5MG/	/N09987/004/
	∂ UPJOHN	5MG	N09987 004
	PREDNISOLONE		
	∂ EON LABS	5MG	N84773 001
/BX/	/HEATHER/	/5MG/	/N80326/001/
	∂ HEATHER	5MG	N80326 001
	/∂/VITARINE/	/5MG/	/N84773/001/

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

	BLEPHAMIDE			
AT	ALLERGAN	0.2%;10%		N12813 002
	a ALLERGAN			
AT	PREDSULFAIR II; PHARMAFAIR	0.2%;10%		N88837 001 DEC 24, 1985
	a PHARMAFAIR			

PREDNISONE

TABLET; ORAL

	FERNISONE			
BX	FERNDALE	5MG		N83364 001
	a FERNDALE			
	PREDNISONE			
	a EON LABS	5MG		N84774 001
	RICHLYN	5MG		N80782 001
AB		5MG		N80782 001
BX	a VITARINE	5MG		N84774 001

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	PROCAINAMIDE HCL			
AB	BOLAR	250MG		N88533 001 DEC 03, 1984
AB		500MG		N88534 001 DEC 03, 1984
AB		750MG		N88535 001 NOV 03, 1984
	a BOLAR	250MG		N88533 001 DEC 03, 1984
	a	500MG		N88534 001 DEC 03, 1984
	a	750MG		N88535 001 NOV 03, 1984

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ACHROMYCIN			
AP	LEDERLE	40MG/VIAL;100MG/VIAL		N50267 002
AP		40MG/VIAL;100MG/VIAL		N50276 001
AP		40MG/VIAL;250MG/VIAL		N50267 003

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

	TETRACYN			
AP	PFIZER	40MG/VIAL;250MG/VIAL		N60285 003
	a	40MG/VIAL;100MG/VIAL		N60285 002

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

	PROCHLORPERAZINE EDISYLATE			
AP	ELKINS SINN	EQ 5MG BASE/ML		N89523 001 MAY 03, 1988
	a ELKINS SINN	EQ 5MG BASE/ML		N89523 001 MAY 03, 1988

PROCHLORPERAZINE MALEATE

TABLET; ORAL

	COMPAZINE			
AB	SKF	EQ 5MG BASE		N10571 001
AB		EQ 10MG BASE		N10571 002
AB		EQ 25MG BASE		N10571 003
	+ SKF	EQ 25MG BASE		N10571 003
	+ SKF	EQ 5MG BASE		N10571 001
	+ SKF	EQ 10MG BASE		N10571 002
	PROCHLORPERAZINE MALEATE			
B*	DURAMED	EQ 5MG BASE		N89484 001 JAN 20, 1987
B*		EQ 10MG BASE		N89485 001 JAN 20, 1987
B*		EQ 25MG BASE		N89486 001 JAN 20, 1987
	a DURAMED	EQ 5MG BASE		N89484 001 JAN 20, 1987
	a	EQ 10MG BASE		N89485 001 JAN 20, 1987
	a	EQ 25MG BASE		N89486 001 JAN 20, 1987

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PROMAZINE HCL			
AP	STERIS	25MG/ML		N84516 001
	SPARINE			
AP	WYETH AYERST	25MG/ML		N10349 008
	a WYETH AYERST	25MG/ML		N10349 008

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL
PROMETHAZINE HCL

	∂ EON LABS	25MG	N85146 001
	∂	50MG	N85146 002
/∂/	/VITARINE/	/25MG/	/N85146/001/
/∂/		/50MG/	/N85146/002/

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL
RYTHMOL

>ADD>	KNOLL	225MG¤	N19151 003
>ADD>			NOV 20, 1992

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

/AA/	/HEATHER/	/15MG/	/N85780/001/
	∂ HEATHER	15MG	N85780 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPHTHAINE

/AT/	/SQUIBB/	/5MG/ML/	/N08883/001/
AT	SQUIBB	0.5%	N08883 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

	∂ EON LABS	32MG	N84014 001
>ADD>	∂	65MG	N83688 001
	∂	65MG	N83870 002
	∂	65MG	N86495 001
/∂/	/VITARINE/	/32MG/	/N84014/001/
>DLT> /∂/		/65MG/	/N83688/001/
/∂/		/65MG/	/N83870/002/
/∂/		/65MG/	/N86495/001/

~~/PROPOXYPHENE HCL 65/~~
~~PROPOXYPHENE HCL 65~~

/AA/	/PARKE/DAVIS/	/65MG/	/N83786/001/
	∂ WARNER CHILCOTT	65MG	N83786 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

/AB/	/SUPERPHARM/	/10MG/	/N71515/001/
			/JUN/08,/1988/
/AB/		/20MG/	/N71516/001/
			/JUN/08,/1988/
	∂ SUPERPHARM	10MG	N71515 001
			JUN 08, 1988
	∂	20MG	N71516 001
			JUN 08, 1988

PROTIRELIN

INJECTABLE; INJECTION
RELEFACT TRH

AP	FERRING	0.5MG/ML	N18087 001
/AP/	/HOECHST/ROUSSEL/	/0.5MG/ML/	/N18087/001/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL

AA	EON LABS	60MG;2.5MG	N88193 001
			MAY 17, 1983
/AA/	/VITARINE/	/60MG;2.5MG/	/N88193/001/
			/MAY/17,/1983/

PYRAZINAMIDE

TABLET; ORAL
PYRAZINAMIDE

AB	+ LEDERLE	500MG	N80157 001
AB	MIKART	500MG¤	N81319 001
			JUN 30, 1992

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

/AP/	/LUITPOLD/	/100MG/ML/	/N80669/001/
	∂ LUITPOLD	100MG/ML	N80669 001

QUINETHAZONE; RESERPINE

/TABLET;/ORAL/
/HYDROMOX/R/
/LEDERLE/ /50MG;0.125MG/ /N13927/001/

ə LEDERLE 50MG;0.125MG N13927 001

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE
ə ELKINS SINN 200MG N83622 001
AB EON LABS 200MG N84631 001
AB 300MG N88072 001
SEP 26, 1983

/ə/QUANTUM/PHARMICS/ /200MG/ /N83622/001/
/AB/ /VITARINE/ /200MG/ /N84631/001/
/AB/ /300MG/ /N88072/001/
/SEP/26,/1983/

RAUWOLFIA SERPENTINA

TABLET; ORAL
/RAUVERID/
/BP/ /FOREST/PHARMS/ /50MG/ /N09255/008/
WOLFINA
ə FOREST PHARMS 50MG N09255 008

RESERPINE

TABLET; ORAL
RESERPINE
BP EON LABS 0.1MG N09838 001
BP 0.25MG N09838 002
/BP/ /VITARINE/ /0.1MG/ /N09838/001/
/BP/ /0.25MG/ /N09838/002/

/SERPATE/
/BP/ /VALE/ /0.1MG/ /N09453/001/
/BP/ /0.25MG/ /N09453/002/
ə VALE 0.1MG N09453 001
ə 0.25MG N09453 002

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
/AP/ /LYPHOMED/ /10MG/ML/ /N71188/001/ /JUL/23,/1987/
/AP/ /15MG/ML/ /N71189/001/ /JUL/23,/1987/
ə LYPHOMED 10MG/ML N71188 001 JUL 23, 1987
ə 15MG/ML N71189 001 JUL 23, 1987

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS
/E/Z/EM/ /460MG/GM;420MG/GM/ /N18509/001/ /AUG/07,/1985/
LAFAYETTE 460MG/GM;420MG/GM N18509 001 AUG 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ə LYPHOMED 9MG/ML N88909 001 FEB 07, 1985
/9MG/ML/ /N88909/001/ /FEB/07,/1985/

/SODIUM/CHLORIDE/23.4%/IN/PLASTIC/CONTAINER/
/LYPHOMED/ /234MG/ML/ /N19329/001/ /APR/22,/1987/
ə LYPHOMED 234MG/ML N19329 001 APR 22, 1987

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
AP MCGAW 1.87GM/100ML¤ N20004 001 APR 21, 1992

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

	NITROPRESS			
AP	ABBOTT	25MG/ML	N71961 001	AUG 01, 1988
	SODIUM NITROPRUSSIDE			
AP	GENSIA	25MG/ML¤	N73465 001	MAR 30, 1992

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

	SODIUM POLYSTYRENE SULFONATE			
/AA/	/ROXANE/	/15GM/60ML/	/N88453/001/	/NOV/17,/1983/
	∂ ROXANE	15GM/60ML	N88453 001	NOV 17, 1983

SODIUM THIOSULFATE

INJECTABLE; INJECTION

	SODIUM THIOSULFATE			
	US ARMY	250MG/ML¤	N20166 001	FEB 14, 1992

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	BETAPACE			
	+ BERLEX	240MG¤	N19865 003	OCT 30, 1992
		80MG¤	N19865 001	OCT 30, 1992
		160MG¤	N19865 002	OCT 30, 1992
	∂	320MG¤	N19865 004	OCT 30, 1992

SPIRONOLACTONE

TABLET; ORAL

	SPIRONOLACTONE			
/AA/	/PARKE/DAVIS/	/25MG/	/N87952/001/	/NOV/18,/1982/
	∂ WARNER CHILCOTT	25MG	N87952 001	NOV 18, 1982

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

	SUCCINYLCHOLINE CHLORIDE			
	/INTL/MEDICATION/	/100MG/VIAL/	/N85400/001/	/FEB/04,/1982/
	∂ INTL MEDICATION	100MG/VIAL	N85400 001	FEB 04, 1982

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE/

	/CREAM;/VAGINAL/			
	/SULTRIN/			
	/JOHNSON/RW/	/3.72;2.86%;3.42%/	/N85794/001/	
	/TABLET;/VAGINAL/			
	/SULTRIN/			
	/JOHNSON/RW/	/184MG;143.75MG;172.5MG/	/N85794/002/	
	/TRIPLE/SULFA/			
	/∂/FOUGERA/	/184MG;143.75MG;172.5MG/	/N88463/001/	/JAN/03,/1985/
	/∂/PHARMADERM/	/184MG;143.75MG;172.5MG/	/N88462/001/	/JAN/03,/1985/

/SULFABENZAMIDE;/SULFACETAMIDE;/SULFATHIAZOLE;/UREA/

	/CREAM;/VAGINAL/			
	/GYNE-SULF/			
/AT/	/∂/AND/W/	/3.72;2.862;3.422;0.642/	/N88607/001/	/JUN/09,/1986/
	/TRIPLE SULFA/			
/AT/	/CLAY/PARK/	/3.72;2.862;3.422;0.642/	/N87285/001/	/NOV/15,/1982/
/AT/	/FOUGERA/	/3.72;2.862;3.422;0.642/	/N86424/001/	
/AT/	/NMC/	/3.72;2.862;3.422;0.642/	/N87864/001/	/SEP/01,/1982/
/AT/	/PHARMADERM/	/3.72;2.862;3.422;0.642/	/N87887/001/	/JUL/23,/1982/
	/VAGILIA/			
/AT/	/LEMMON/	/3.72;2.862;3.422;0.642/	/N88821/001/	/NOV/09,/1987/

SULFAMETHIZOLE

TABLET; ORAL

	/PROLAB/			
/AA/	/FOREST PHARMS/	/500MG/	/N80273/001/	
	∂ FOREST PHARMS	500MG	N80273 001	

TABLET; ORAL

SPIRONOLACTONE

/AB/ /PARKE/DAVIS/ /25MG/ /N87952/001/ /NOV/18,/1982/

∂ WARNER CHILCOTT 25MG N87952 001 NOV 18, 1982

SULFAMETHIZOLE

TABLET; ORAL

/PROVLAS/

/AB/ /FOREST/PHARMS/ /500MG/ /N60273/001/ N60273 001

∂ FOREST PHARMS 500MG

SULFAMETHIZOLE

TABLET; ORAL

THIOSULFIL

/AB//+//WYETH/AYERST/ /500MG/ /N08565/004/

+ WYETH AYERST 500MG N08565 004

SULFAMETHOXAZOLE

TABLET; ORAL

/URODAK/

/AB/ /SHIONOGI/ /500MG/ /N87307/001/

∂ SHIONOGI 500MG N87307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP CETUS BEN VENUE 80MG/ML;16MG/ML¤ N72383 001 APR 29, 1992

AP STERLING WINTHROP 80MG/ML;16MG/ML¤ N73199 001 SEP 11, 1992

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB EON LABS 400MG;80MG N18598 001 MAY 19, 1982

/AB/ /INTERPHARM/ /400MG;80MG/ /N71299/001/ /OCT/27,/1987/

/AB/ /800MG;160MG/ /N71300/001/ /OCT/27,/1987/

B* INTERPHARM 400MG;80MG N71299 001 OCT 27, 1987

B* 800MG;160MG N71300 001 OCT 27, 1987

/AB/ /MARTEC/ /400MG;80MG/ /N72408/001/ /DEC/07,/1988/

∂ MARTEC 400MG;80MG N72408 001 DEC 07, 1988

/B*/ /PHARM/BASICS/ /400MG;80MG/ /N70203/001/ /NOV/08,/1985/

/B*/ /800MG;160MG/ /N70204/001/ /NOV/08,/1985/

∂ PHARM BASICS 400MG;80MG N70203 001 NOV 08, 1985

∂ 800MG;160MG N70204 001 NOV 08, 1985

/AB/ /VITARINE/ /400MG;80MG/ /N18598/001/ /MAY/19,/1982/

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB EON LABS 800MG;160MG N18598 004 MAY 19, 1982

/AB/ /MARTEC/ /800MG;160MG/ /N72417/001/ /DEC/07,/1988/

∂ MARTEC 800MG;160MG N72417 001 DEC 07, 1988

/AB/ /VITARINE/ /800MG;160MG/ /N18598/004/ /MAY/19,/1982/

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

∂ EON LABS 500MG N86184 001

/∂/VITARINE/ /500MG/ /N86184/001/

SULFISOXAZOLE

TABLET; ORAL

/SULFALAR/

/AB/ /PARKE/DAVIS/ /500MG/ /N84955/001/

∂ PARKE DAVIS 500MG N84955 001

SULFISOXAZOLE

/AB/ /WEST/WARD/ /500MG/ /N80379/001/

∂ WEST WARD 500MG N80379 001

SULINDAC

TABLET; ORAL

SULINDAC

AB LEMMON 150MG¤ N72972 001 FEB 28, 1992

AB 200MG¤ N72973 001 FEB 28, 1992

TALBUTAL

/TABLET;/ORAL/

/LOTUSATE/

/STERLING/ /120MG/ /N09410/005/

∂ STERLING 120MG N09410 005

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION
OSTEOSCAN
> DLT > /MALLINCKRODT/ /N/A/ /N17454/001/
> ADD > @ MALLINCKRODT N/A N17454 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION
RBC-SCAN
CADEMA N/A¤ N20063 001
JUN 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
CARDIOLITE
/DUPONT/ /N/A/ /N19785/001/
/DEC/21/1990/
DUPONT MERCK N/A N19785 001
DEC 21, 1990

TEMAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
OMNIFLOX
/+//ABBOTT/ /EQ/600MG/BASE¤/ /N20043/004/
/JAN/30/1992/
/EQ/400MG/BASE¤/ /N20043/003/
/JAN/30/1992/
@ ABBOTT EQ 400MG BASE¤ N20043 003
JAN 30, 1992
@ EQ 600MG BASE¤ N20043 004
JAN 30, 1992

TEMAZEPAM

TENIPOSIDE

INJECTABLE; INJECTION
VUMON
BRISTOL MYERS SQUIBB 10MG/ML¤ N20119 001
JUL 14, 1992

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN
+ ABBOTT 2MG N19057 002
AUG 07, 1987
/+/ /1MG/ /N19057/004/
/AUG/07/1987/
/2MG/ /N19057/002/
/AUG/07/1987/
10MG N19057 004
AUG 07, 1987

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL
AO GYNEX 200MG/ML N09165 003
@ 200MG/ML N09165 001
/AO/ /SQUIBB/ /200MG/ML/ /N09165/003/
/@/ /200MG/ML/ /N09165/001/

TETRACYCLINE

SYRUP; ORAL
/HYDROCHLORIDE/
/AB/ /BARRE/ /EQ 125MG HCL/5ML/ /N60633/001/
TETRACYCLINE
AB BARRE EQ 125MG HCL/5ML N60633 001

TETRACYCLINE HYDROCHLORIDE

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

/B*/	/PHARM/BASICS/	/15MG/	/N70489/001/ /JUL/07,/1986/
/B*/		/30MG/	/N70490/001/ /JUL/07,/1986/
	ə PHARM BASICS	15MG	N70489 001 JUL 07, 1986
	ə	30MG	N70490 001 JUL 07, 1986

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
/CYCLOPAR/

/AB/	/PARKE/DAVIS/	/250MG/	/N61725/001/
/AB/		/250MG/	/N62175/001/
/AB/		/250MG/	/N62332/001/
/AB/		/500MG/	/N61725/002/
/AB/		/500MG/	/N62332/002/

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
/CYCLOPAR/

	ə WARNER CHILCOTT	250MG	N61725 001
	ə	250MG	N62175 001
	ə	250MG	N62332 001
	ə	500MG	N61725 002
	ə	500MG	N62332 002

ROBITET

/AB/	/ROBINS/	/250MG/	/N61734/001/
/AB/		/500MG/	/N61734/002/
AB	WYETH AYERST	250MG	N61734 001
AB		500MG	N61734 002

SUMYCIN

> ADD >	ə APOTHECON	100MG	N60429 002
> ADD >	ə	125MG	N60429 004
> DLT >/AB/	/SQUIBB/	/100MG/	/N60429/002/
> DLT >/AB/		/125MG/	/N60429/004/

TETRACYCLINE HCL

AB	EON LABS	250MG	N61471 001
	ə	500MG	N61471 002 SEP 06, 1988
> DLT >/AB/	/MK/	/125MG/	/N60173/001/
> ADD >	MK	125MG	N60173 001
/AB/	/PARKE/DAVIS/	/250MG/	/N62300/001/
/AB/		/500MG/	/N62300/002/
> DLT >/AB/	/RICHLYN/	/100MG/	/N60469/002/
> ADD >	RICHLYN	100MG	N60469 002
/AB/	/VITARINE/	/250MG/	/N61471/001/
/ə/		/500MG/	/N61471/002/ /SEP/06,/1988/
AB	WARNER CHILCOTT	250MG	N62300 001
AB		500MG	N62300 002

/INJECTABLE;/INJECTION/
/ACHROMYCIN/

/AP/	/LEDERLE/	/100MG/VIAL/	/N50267/002/
/AP/		/100MG/VIAL/	/N50276/001/
/AP/		/250MG/VIAL/	/N50267/003/

/TETRACYN/

/AP/	/PFIZER/	/250MG/VIAL/	/N60285/003/
/ə/		/100MG/VIAL/	/N60285/002/

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
SOMOPHYLLIN-CRT

/BC/	/FISONS/	/50MG/	/N87763/001/ /FEB/27,/1985/
/BC/		/100MG/	/N87194/001/
/BC/		/200MG/	/N88382/001/ /FEB/27,/1985/
/BC/		/250MG/	/N87193/001/
/BC/		/300MG/	/N88383/001/ /FEB/27,/1985/
BC	GRAHAM LABS	50MG	N87763 001 FEB 27, 1985
BC		100MG	N87194 001
BC		200MG	N88382 001 FEB 27, 1985
BC		250MG	N87193 001
BC		300MG	N88383 001 FEB 27, 1985

THEO-24

/BC/	/SEARLE/	/100MG/	/N87942/001/ /AUG/22,/1983/
/BC/		/200MG/	/N87943/001/ /AUG/22,/1983/
/BC/		/300MG/	/N87944/001/ /AUG/22,/1983/
		/400MG¤/	/N81034/001/ /FEB/28,/1992/
BC	WHITBY	100MG	N87942 001 AUG 22, 1983
BC		200MG	N87943 001 AUG 22, 1983
BC		300MG	N87944 001 AUG 22, 1983
		400MG¤	N81034 001 FEB 28, 1992

THEOPHYLLINE

	ə EON LABS	260MG	N87462 001 MAY 11, 1982
/ə/	/VITARINE/	/260MG/	/N87462/001/ /MAY/11,/1982/

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	40MG/100ML¤	N19826 001 AUG 14, 1992

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	80MG/100ML¤	N19826 002 AUG 14, 1992

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	160MG/100ML¤	N19826 003	AUG 14, 1992

THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	200MG/100ML¤	N19826 004	AUG 14, 1992

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	320MG/100ML¤	N19826 006	AUG 14, 1992

THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	400MG/100ML¤	N19826 005	AUG 14, 1992

TABLET, EXTENDED RELEASE; ORAL

T-PHYL

BC	PURDUE FREDERICK	200MG	N88253 001	AUG 17, 1983

THEO-DUR

> ADD >	AB	+ KEY PHARMS	450MG	N89131 001	JUN 25, 1986
> ADD >					

/THEOCONTIN/

/BC/	/PURDUE/FREDERICK/	/200MG/	/N88253/001/	/AUG/17,/1983/

THEOPHYLLINE

> ADD >	AB	SIDMAK	450MG¤	N81236 001	NOV 09, 1992
> ADD >					

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

/AP/	/LUITPOLD/	/100MG/ML/	/N80667/001/
	ə LUITPOLD	100MG/ML	N80667 001
/AP/	/PARKE/DAVIS/	/100MG/ML/	/N80770/001/
	ə PARKE DAVIS	100MG/ML	N80770 001

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

/AB/	/PAR/	/150MG/	/N89764/001/ /FEB/09,/1988/
/AB/		/200MG/	/N89765/001/ /FEB/09,/1988/
	ə PAR	150MG	N89764 001 FEB 09, 1988
	ə	200MG	N89765 001 FEB 09, 1988

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

THIOTHIXENE HCL INTENSOL

AA	ROXANE	EQ 5MG BASE/ML¤	N73494 001	JUN 30, 1992

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

/B*/	/PHARM/BASICS/	/5MG/	/N72001/001/ /JAN/10,/1989/
/B*/		/10MG/	/N72002/001/ /JAN/10,/1989/
/B*/		/20MG/	/N72003/001/ /JAN/10,/1989/
	ə PHARM BASICS	5MG	N72001 001 JAN 10, 1989
	ə	10MG	N72002 001 JAN 10, 1989
	ə	20MG	N72003 001 JAN 10, 1989

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP	ABBOTT	EQ 40MG BASE/ML¤	N63116 001	MAY 18, 1992
AP	GENSIA	EQ 40MG BASE/ML¤	N63100 001	JAN 30, 1992

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

/AB/	/INTERPHARM/	/250MG/	/N71270/001/ /SEP/23,/1986/
/AB/		/500MG/	/N71271/001/ /SEP/23,/1986/
B*	INTERPHARM	250MG	N71270 001 SEP 23, 1986
B*		500MG	N71271 001 SEP 23, 1986
/B*/	/PHARM/BASICS/	/100MG/	/N71355/001/ /JAN/11,/1988/
/B*/		/250MG/	/N70168/001/ /APR/02,/1986/
/B*/		/500MG/	/N70169/001/ /APR/02,/1986/
	ə PHARM BASICS	100MG	N71355 001 JAN 11, 1988
	ə	250MG	N70168 001 APR 02, 1986
	ə	500MG	N70169 001 APR 02, 1986

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

AB	EON LABS	500MG	N12678 001
/AB/	/PARKE/DAVIS/	/500MG/	/N86047/001/
	ə PARKE DAVIS	500MG	N86047 001
/AB/	/VITARINE/	/500MG/	/N12678/001/

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

AB	BAKER CUMMINS	EQ 400MG BASE¤	N73392 001 JAN 24, 1992
AB	GENEVA	EQ 400MG BASE¤	N73462 001 APR 30, 1992
AB	LEMMON	EQ 400MG BASE¤	N73519 001 MAY 29, 1992
AB	PUREPAC	EQ 400MG BASE¤	N73308 001 JAN 24, 1992

TOLMETIN SODIUM

TABLET; ORAL

TOLECTIN 600

AB	+ JOHNSON RW	EQ 600MG BASE	N17628 002 MAR 08, 1989

TOLMETIN SODIUM

AB	GENEVA	EQ 200MG BASE¤	N73588 001 JUL 31, 1992
AB	PUREPAC	EQ 600MG BASE¤	N73527 001 JUN 30, 1992

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCL

/B*/	/PHARM/BASICS/	/50MG/	/N70491/001/ /APR/29,/1987/
/B*/		/100MG/	/N70492/001/ /APR/29,/1987/
	ə PHARM BASICS	50MG	N70491 001 APR 29, 1987
	ə	100MG	N70492 001 APR 29, 1987

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

	ə EON LABS	4MG	N86171 001
/ə/	/VITARINE/	/4MG/	/N86171/001/

TRIDIHEXETHYL CHLORIDE

/TABLET;/ORAL/			
/PATHILON/			
/LEDERLE/		/25MG/	/N09489/005/
	ə LEDERLE	25MG	N09489 005

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
SURMONTIL

/AB/	/WYETH/AYERST/	/EQ 25MG BASE/	/N16792/001/
/AB/		/EQ 50MG BASE/	/N16792/002/
/AB/!+!		/EQ 100MG BASE/	/N16792/003/
			/SEP/15,/1982/
	+ WYETH AYERST	EQ 100MG BASE	N16792 003 SEP 15, 1982
		EQ 25MG BASE	N16792 001
		EQ 50MG BASE	N16792 002

/TRIMIPRAMINE/MALEATE;/

/B*/	/PHARM/BASICS/	/EQ/25MG/BASE/	/N71283/001/ /DEC/08,/1987/
/B*/		/EQ/50MG/BASE/	/N71284/001/ /DEC/08,/1987/
/B*/		/EQ/100MG/BASE/	/N71285/001/ /DEC/08,/1987/
	TRIMIPRAMINE MALEATE		
	ə EON LABS	EQ 25MG BASE	N71832 001 SEP 10, 1987
	ə	EQ 50MG BASE	N71833 001 SEP 10, 1987
	ə	EQ 100MG BASE	N71834 001 SEP 10, 1987
	ə PHARM BASICS	EQ 25MG BASE	N71283 001 DEC 08, 1987
	ə	EQ 50MG BASE	N71284 001 DEC 08, 1987
	ə	EQ 100MG BASE	N71285 001 DEC 08, 1987
	TRIMIPRAMINE MALEATE		
/ə/	/VITARINE/	/EQ/25MG/BASE/	/N71832/001/ /SEP/10,/1987/
/ə/		/EQ/50MG/BASE/	/N71833/001/ /SEP/10,/1987/
/ə/		/EQ/100MG/BASE/	/N71834/001/ /SEP/10,/1987/

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL
GYNE-SULF

AT	G AND W	3.7%;2.86%;3.42%	N88607 001 JUN 09, 1986
AT	SULTRIN JOHNSON RW	3.7%;2.86%;3.42%	[illegible]

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL
TRIPLE SULFA

AT	CLAY PARK	3.7%;2.86%;3.42%	N87285 001 NOV 15, 1982
AT	FOUGERA	3.7%;2.86%;3.42%	N86424 001
AT	NMC	3.7%;2.86%;3.42%	N87864 001 SEP 01, 1982
	TRYSUL		
AT	SAVAGE	3.7%;2.86%;3.42%	N87887 001 JUL 23, 1982
	VAGILIA		
	ə LEMMON	3.7%;2.86%;3.42%	N88821 001 NOV 09, 1987

TABLET; VAGINAL
SULTRIN

	JOHNSON RW	184MG;143.75MG;172.5MG	N05794 002
	TRIPLE SULFA		
	ə FOUGERA	184MG;143.75MG;172.5MG	N88463 001 JAN 03, 1985
	ə PHARMADERM	184MG;143.75MG;172.5MG	N88462 001 JAN 03, 1985

TRISULFAPYRIMIDINES

SUSPENSION; ORAL
/SULFADIAZINE/

/AB/	/FOREST/PHARMS/	/500MG/5ML/	/N80100/001/
	ə FOREST PHARMS	500MG/5ML	N80100 001

URACIL MUSTARD

CAPSULE; ORAL
URACIL MUSTARD

	ROBERTS	1MG	N12892 001
	/UPJOHN/	/1MG/	/N12892/001/

VALPROIC ACID

SYRUP; ORAL
VALPROIC ACID

AA	COPLEY	250MG/5ML¤	N73178 001 AUG 25, 1992

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM; VAGINAL
GYNE-SULF
AT G AND W 3.7%;2.86%;3.42% N88607 001 JUN 09, 1986

SULTRIN
AT JOHNSON RW 3.7%;2.86%;3.42% N85794 001

SYRUP; ORAL
VALPROIC ACID
AA COPLEY 250MG/5ML¤ N73178 001 AUG 25, 1992

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HCL
AP ABBOTT EQ 500MG BASE/VIAL¤ N62931 001 OCT 29, 1992
AP EQ 1GM BASE/VIAL¤ N62933 001 OCT 29, 1992

VECURONIUM BROMIDE

INJECTABLE; INJECTION
NORCURON
ORGANON 20MG/VIAL¤ N18776 003 JAN 03, 1992

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN
+ ELAN 180MG¤ N19614 003 JAN 09, 1992

TABLET; ORAL
VERAPAMIL HCL
/B*/ /CHELSEA/ /80MG/ /N70421/001/ /SEP/17,/1986/
/B*/ /120MG/ /N70422/001/ /SEP/17,/1986/
AB GENEVA 40MG¤ N73168 001 JUL 31, 1992
/AB/ /PARKE/DAVIS/ /80MG/ /N70340/001/ /AUG/20,/1986/
/AB/ /120MG/ /N70341/001/ /AUG/20,/1986/
∂ PARKE DAVIS 80MG N70340 001 AUG 20, 1986
∂ 120MG N70341 001 AUG 20, 1986

TABLET, EXTENDED RELEASE; ORAL
ISOPTIN SR
AB + KNOLL 240MG N19152 001 DEC 16, 1986
VERAPAMIL HCL
AB BAKER CUMMINS 240MG¤ N73568 001 JUL 31, 1992

VINBLASTINE SULFATE

INJECTABLE; INJECTION
/VELSAR/
/AP/ /BULL/ /10MG/VIAL/ /N89565/001/ /AUG/18,/1987/
VINBLASTINE SULFATE
AP BULL 10MG/VIAL N89565 001 AUG 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE
>DLT>/AP/ /ABIC/ /1MG/ML/ /N70873/001/ /FEB/19,/1987/
>DLT>
>ADD>
>ADD>
∂ ABIC 1MG/ML N70873 001 FEB 19, 1987

VITAMIN A

CAPSULE; ORAL
AQUASOL A
AA ASTRA
50,000 USP UNITS N83080 001
/AA/ /USV/ 25,000 USP UNITS N83080 002
/50,000 USP UNITS/ /N83080/001/
/25,000/USP/UNITS/ /N83080/002/

VITAMIN A PALMITATE

CAPSULE; ORAL
VITAMIN A
∂ ELKINS SINN EQ 50,000 UNITS BASE N85479 001
/∂/QUANTUM/PHARMICS/ /EQ/50,000/UNITS/BASE/ /N85479/001/

WARFARIN SODIUM

TABLET; ORAL
/WARFARIN/SODIUM/
/B*/ /PHARM/BASICS/ /2MG/ /N88719/001/ /JUN/27,/1985/
/B*/ /2.5MG/ /N88720/001/ /AUG/06,/1985/
/B*/ /5MG/ /N88721/001/ /JUL/02,/1985/

WARFARIN SODIUM

TABLET; ORAL
/WARFARIN/SODIUM/

∂ PHARM BASICS	2MG	N88719 001 JUN 27, 1985
∂	2.5MG	N88720 001 AUG 06, 1985
∂	5MG	N88721 001 JUL 02, 1985

ZALCITABINE

TABLET; ORAL
HIVID

+ ROCHE	0.75MG¤	N20199 002 JUN 19, 1992
	0.375MG¤	N20199 001 JUN 19, 1992

ACETAMINOPHEN

SUPPOSITORY; RECTAL
ACEPHEN
G AND W — 120MG¤ — N72218 001 MAR 27, 1992
325MG¤ — N72344 001 MAR 27, 1992
650MG¤ — N72237 001 MAR 27, 1992

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

> DLT > /OINTMENT;/TOPICAL/
> DLT > /LANABIOTIC/
> DLT > /COMBE/ — /400/UNITS/GM;40MG/GM;EQ/5MG/BASE/GM/ /5,000/UNITS/GM/ — /N62499/001/ /JUN/03,/1985/

> ADD > ə COMBE — 400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM 5,000 UNITS/GM — N62499 001 JUN 03, 1985

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
MICROCOL
JOHNSON AND JOHNSON — 0.5%¤ — N72292 001 JAN 28, 1992

STERI-STAT
MATRIX MEDCL — 4% — N70104 001 JUL 24, 1986
/MEDCL/SYSTEMS/ — /4%/ — /N70164/001/ /JUL/24,/1986/

CLEMASTINE FUMARATE

TABLET; ORAL
TAVIST-1
SANDOZ — 1.34MG¤ — N17661 003 AUG 21, 1992

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
TAVIST-D
SANDOZ — 1.34MG;75MG¤ — N18298 002 AUG 21, 1992

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
/RESPORAL/
/PIONEER/PHARMS/ — /6MG;120MG/ — /N89139/001/ /JUN/16,/1988/
ə PIONEER PHARMS — 6MG;120MG — N89139 001 JUN 16, 1988

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
CUMBERLAND SWAN — 12.5MG/5ML¤ — N73611 001 AUG 20, 1992

SILPHEN
SILARX — 12.5MG/5ML¤ — N72646 001 FEB 27, 1992

IBUPROFEN

TABLET; ORAL
IBUPROFEN
> DLT > /MEDICOPHARMA/ — /200MG/ — /N71639/001/ /FEB/02,/1988/
> DLT > TAG — 200MG¤ — N73141 001 MAY 29, 1992

> ADD > VINTAGE — 200MG — N71639 001 FEB 02, 1988

INSULIN BIOSYNTHETIC HUMAN; INSULIN SUSP ISOPHANE BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN 50/50
LILLY — 50 UNITS/ML;50 UNITS/ML¤ — N20100 001 APR 29, 1992

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
BARRE — 1MG/5ML¤ — N73187 001 SEP 15, 1992
PERRIGO — 1MG/5ML¤ — N73243 001 JAN 21, 1992
ROXANE — 1MG/5ML¤ — N73079 001 APR 30, 1992

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL
LOPERAMIDE HCL
PERRIGO 2MG N74194 001
OCT 30, 1992

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE
COPLEY 2% N74030 001
OCT 30, 1992

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION
BRONCHO SALINE
BLAIREX 0.9% N19912 001
SEP 03, 1992

SODIUM MONOFLUOROPHOSPHATE

PASTE; DENTAL
EXTRA-STRENGTH AIM
/S/CHESEBROUGH/PONDS/ /1.2%/ /N19518/001/
/JUN/03,/1987/
CHESEBROUGH PONDS 1.2% N19518 001
JUN 03, 1987

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 11 / JAN '92 - NOV '92

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER

ABBOTT LABS	10GM/100ML;0.9GM/100ML	N72562
		OCT 30, 1992

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER

ABBOTT LABS	10GM/100ML;5GM/100ML	N72563
		OCT 30, 1992

DEXTRAN 75 6% INVERTED SUGAR 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% GENTRAN 75 AND 10% TRAVERT

TRAVENOL LABS	6GM/100ML;10GM/100ML; 0.9GM/100ML	N08788

UROKINASE

INJECTABLE; INJECTION
BREOKINASE

STERLING DRUG	250,000 IU/VIAL	N17873

ORPHAN DRUG PRODUCT DESIGNATIONS

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG." SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

WHEN A PRODUCT IS GRANTED ORPHAN DRUG DESIGNATION, IT WILL APPEAR IN THIS SECTION. ONCE A BIOLOGICAL OR DRUG PRODUCT IS LICENSED/APPROVED FOR MARKETING, IT WILL BE LISTED IN THIS SECTION AND ASTERISKED, AS APPROPRIATE, TO DENOTE MARKETING/EXCLUSIVE APPROVAL STATUS. IN ADDITION, THE EXCLUSIVITY EXPIRATION DATE WILL BE DISPLAYED FOLLOWING THE APPROVED DESIGNATED INDICATION(S).

THE FOLLOWING DRUGS AND BIOLOGICALS HAVE BEEN GRANTED ORPHAN DRUG DESIGNATION PURSUANT TO SECTION 526 OF THE FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY THE ORPHAN DRUG ACT [PUBLIC LAW 97-414].

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS
[Approved for Marketing*]
[Exclusive Approval**]

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: AI-RSA TRADE: NOT ESTABLISHED	TREATMENT OF AUTOIMMUNE UVEITIS.	AUTOIMMUNE, INC
GENERIC: ALDESLEUKIN TRADE: PROLEUKIN*/**	TREATMENT OF PRIMARY IMMUNODEFICIENCY DISEASE ASSOCIATED WITH T-CELL DEFECTS.*/** [MAY 05, 1999]	CETUS
GENERIC: ANANAIN, COMOSAIN TRADE: VIANAIN	FOR THE ENZYMATIC DEBRIDEMENT OF SEVERE BURNS.	GENZYME CORPORATION
GENERIC: ANTIHEMOPHILIC FACTOR, HUMAN TRADE: HUMATE P	TREATMENT OF PATIENTS WITH VON WILLEBRAND'S DISEASE.	BEHRINGWERKE AKTIENGESELLSCHAFT
GENERIC: ANTITHROMBIN III TRADE: THROMBATE III*/**	USE AS REPLACEMENT THERAPY IN CONGENITAL DEFICIENCY OF ANTITHROMBIN-III FOR PREVENTION AND TREATMENT OF OF THROMBOSIS AND PULMONARY EMBOLI. [DEC 13, 1996]	CUTTER BIOLOGICAL

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: BOTULINUM TOXIN TYPE A TRADE: NOT ESTABLISHED	TREATMENT OF SYNKINETIC CLOSURE OF THE EYELID ASSOCIATED WITH VII CRANIAL NERVE ABERRANT REGENERATION.	BIOPURE CORPORATION
GENERIC: BOTULINUM TOXIN TYPE B TRADE: NOT ESTABLISHED	TREATMENT OF CERVICAL DYSTONIA.	ATHENA NEUROSCIENCES, INC
GENERIC: CILIARY NEUROTROPHIC FACTOR TRADE: NOT ESTABLISHED	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	ROGENERON PHARMACEUTICALS, INC
GENERIC: CILIARY NEUROTROPHIC FACTOR, RECOMBINANT HUMAN TRADE: NOT ESTABLISHED	TREATMENT OF SPINAL MUSCULAR ATROPHIES. TREATMENT OF MOTOR NEURON DISEASE (INCLUDING AMYOTROPHIC LATERAL SCLEROSIS, PROGRESSIVE MUSCULAR ATROPHY, PROGRESSIVE BULBAR PALSY, AND PRIMARY LATERAL SCLEROSIS).	SYNTEX-SYNERGEN NEUROSCIENCE
GENERIC: COAGULATION FACTOR IX TRADE: MONONINE*/**	REPLACEMENT TREATMENT AND PROPHYLAXIS OF THE HEMORRHAGIC COMPLICATIONS OF HEMOPHILIA B. [AUG 20, 1999]	ARMOUR PHARMACEUTICAL
GENERIC: CYSTIC FIBROSIS GENE THERAPY TRADE: NOT ESTABLISHED	TREATMENT OF CYSTIC FIBROSIS.	GENZYME CORPORATION
GENERIC: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR TRADE: NOT ESTABLISHED	FOR CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN REPLACEMENT THERAPY IN CYSTIC FIBROSIS PATIENTS.	GENZYME CORPORATION
GENERIC: C1-ESTERASE INHIBITOR, HUMAN, PASTEURIZED TRADE: NOT ESTABLISHED	PREVENTION AND/OR TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA.	BEHRINGWERKE AKTIENGESELLSCHAFT

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: HERPES SIMPLEX VIRUS GENE TRADE: NOT ESTABLISHED	TREATMENT OF PRIMARY AND METASTATIC BRAIN TUMORS.	GENETIC THERAPY, INC
GENERIC: HIV NEUTRALIZING ANTIBODIES TRADE: IMMUPATH	TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	HEMACARE CORPORATION
GENERIC: HUMAN IMMUNODEFICIENCY VIRUS IMMUNE GLOBULIN TRADE: NOT ESTABLISHED	TREATMENT OF HIV-INFECTED PREGNANT WOMEN AND INFANTS OF HIV-INFECTED MOTHERS.	ABBOTT LABORATORIES
GENERIC: IMMUNE GLOBULIN INTRAVENOUS, HUMAN TRADE: IVEEGAM, IMMUNO	TREATMENT OF POLYMYOSITIS/DERMATOMYOSITIS.	IMMUNO CLINICAL RESEARCH CORPORATION
GENERIC: IMPORTED FIRE ANT VENOM, ALLERGENIC EXTRACT TRADE: NOT ESTABLISHED	FOR SKIN TESTING OF VICTIMS OF FIRE ANT STINGS TO CONFIRM FIRE ANT SENSITIVITY AND IF POSITIVE, FOR USE AS IMMUNOTHERAPY FOR THE PREVENTION OF IgE-MEDIATED ANAPHYLACTIC REACTIONS.	ALK LABORATORIES, INC
GENERIC: INTERFERON (RECOMBINANT HUMAN, BETA) TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE NON-A, NON-B HEPATITIS.	BIOGEN, INC
GENERIC: INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT TRADE: ANTRIL	PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE IN TRANSPLANT RECIPIENTS.	SYNERGEN, INC
GENERIC: PROTEIN C CONCENTRATE TRADE: PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR REPLACEMENT THERAPY IN PATIENTS WITH CONGENITAL OR ACQUIRED PROTEIN C DEFICIENCY FOR THE PREVENTION AND TREATMENT OF WARFARIN-INDUCED SKIN NECROSIS DURING ORAL ANTICOAGULATION. FOR REPLACEMENT THERAPY IN CONGENITAL PROTEIN C DEFICIENCY FOR THE PREVENTION AND TREATMENT OF THROMBOSIS, PULMONARY EMBOLI, AND PURPURA FULMINANS.	IMMUNO CLINICAL RESEARCH CORPORATION

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: SARGRAMOSTIM TRADE: LEUKINE*/**	TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANT, FOR THE PROMOTION OF EARLY ENGRAFTMENT, AND FOR THE TREATMENT OF GRAFT FAILURE AND DELAY OF ENGRAFTMENT.*/** [DEC 31, 1998] TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANTS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA, HODGKIN'S DISEASE AND ACUTE LYMPHOBLASTIC LEUKEMIA.*/** [MAR 05, 1998]	IMMUNEX
GENERIC: SECRETORY LEUKOCYTE PROTEASE INHIBITOR TRADE: NOT ESTABLISHED	TREATMENT OF BRONCHOPULMONARY DYSPLASIA.	SYNERGEN, INC
GENERIC: TECHNETIUM TC99M MURINE MONOCLONAL ANTIBODY (IGG2A) TO BCE TRADE: IMMURAID-LL-2[99mTc]	DIAGNOSTIC IMAGING IN THE EVALUATION OF THE EXTENT OF DISEASE IN PATIENTS WITH HISTOLOGICALLY CONFIRMED DIAGNOSIS OF NON-HODGKIN'S B-CELL LYMPHOMA, ACUTE B-CELL LYMPHOBLASTIC LEUKEMIA (IN CHILDREN AND ADULTS), AND CHRONIC B-CELL LYMPHOCYTIC LEUKEMIA.	IMMUNOMEDICS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS
[Approved for Marketing*]
[Exclusive Approval**]

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALLOPURINOL SODIUM TRADE: ZYLOPRIM FOR INJECTION	MANAGEMENT OF PATIENTS WITH LEUKEMIA, LYMPHOMA, AND SOLID TUMOR MALIGNANCIES WHO ARE RECEIVING CANCER THERAPY WHICH CAUSES ELEVATIONS OF SERUM AND URINARY URIC ACID LEVELS AND WHO CANNOT TOLERATE ORAL THERAPY.	BURROUGHS WELLCOME COMPANY
GENERIC: ANARITIDE ACETATE TRADE: AURICULIN	IMPROVEMENT OF EARLY RENAL ALLOGRAFT FUNCTION FOLLOWING RENAL TRANSPLANTATION. TREATMENT OF PATIENTS WITH ACUTE RENAL FAILURE.	SCIOS, INC
GENERIC: ARGININE BUTYRATE TRADE: NOT ESTABLISHED	TREATMENT OF BETA-HEMOGLOBINOPATHIES AND BETA-THALASSEMIA.	SUSAN P. PERRINE, M.D.
GENERIC: BACLOFEN (INTRATHECAL) TRADE: LIORESAL	TREATMENT OF INTRACTABLE SPASTICITY CAUSED BY SPINAL CORD INJURY, MULTIPLE SCLEROSIS, AND OTHER SPINAL DISEASES (INCLUDING SPINAL ISCHEMIA, SPINAL TUMOR, TRANSVERSE MYELITIS, CERVICAL SPONDYLOSIS, AND DEGENERATIVE MYELOPATHY.	MEDTRONIC, INC
GENERIC: BUTYRYLCHOLINESTERASE TRADE: NOT ESTABLISHED	FOR THE REDUCTION AND CLEARANCE OF TOXIC BLOOD LEVELS OF COCAINE ENCOUNTERED DURING A DRUG OVERDOSE. TREATMENT OF POST-SURGICAL APNEA.	PHARMAVENE, INCORPORATED
GENERIC: DAPSONE TRADE: DAPSONE	FOR THE COMBINATION TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA IN CONJUNCTION WITH TRIMETHOPRIM.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: DIANEAL PD-2 PERITONEAL DIALYSIS SOLN WITH 1.1% AMINO ACIDS TRADE: NUTRINEAL PD-2 PERITONEAL DIALYSIS SOLN WITH 1.1% AMINO ACIDS	FOR USE AS A NUTRITIONAL SUPPLEMENT FOR THE TREATMENT OF MALNOURISHMENT IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS.	BAXTER HEALTHCARE CORPORATION
GENERIC: DIAZEPAM VISCOUS SOLUTION FOR RECTAL ADMINISTRATION TRADE: DIASTAT	TREATMENT OF ACUTE REPETITIVE SEIZURES.	UPSHER SMITH LABORATORIES, INC
GENERIC: FIAU TRADE: NOT ESTABLISHED	ADJUNCTIVE TREATMENT OF CHRONIC ACTIVE HEPATITIS B.	OCLASSEN PHARMACEUTICALS, INC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: HALOFANTRINE HCL TRADE: HALFAN*/**	TREATMENT OF MILD TO MODERATE ACUTE MALARIA CAUSED BY SUSCEPTIBLE STRAINS OF P. FALCIPARUM AND P. VIVAX. [JUL 24, 1999]	SMITHKLINE BEECHAM
GENERIC: HUMAN THYROID STIMULATING HORMONE (TSH) TRADE: THYROGEN	AS AN ADJUNCT IN THE DIAGNOSIS OF THYROID CANCER.	GENZYME CORPORATION
GENERIC: L-BACLOFEN TRADE: NEURALGON	TREATMENT OF INTRACTABLE SPASTICITY IN CHILDREN WITH CEREBRAL PALSY.	WTD, INC
GENERIC: L-THREONINE TRADE: NOT ESTABLISHED	TREATMENT OF SPASTICITY ASSOCIATED WITH FAMILIAL SPASTIC PARAPARESIS.	INTERNEURON PHARMACEUTICALS, INC
GENERIC: LEVOCARNITINE TRADE: CARNITOR*/**	GENETIC CARNITINE DEFICIENCY.* TREATMENT OF MANIFESTATIONS OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE (ESRD) WHO REQUIRE DIALYSIS. PREVENTION OF SECONDARY CARNITINE DEFICIENCY IN VALPROIC ACID TOXICITY. TREATMENT OF SECONDARY CARNITINE DEFICIENCY IN VALPROIC ACID TOXICITY.	SIGMA TAU
GENERIC: LIOTHYRONINE SODIUM TRADE: TRIOSTAT*/**	TREATMENT OF MYXEDEMA COMA/PRE-COMA. [DEC 31, 1998]	SMITHKLINE BEECHAM
GENERIC: LOXORIBINE TRADE: NOT ESTABLISHED	TREATMENT OF COMMON VARIABLE IMMUNODEFICIENCY.	R.W. JOHNSON RESEARCH INSTITUTE
GENERIC: MELPHALAN TRADE: ALKERAN FOR INJECTION	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA FOR WHOM ORAL THERAPY IS INAPPROPRIATE. FOR USE IN HYPERTHERMIC REGIONAL LIMB PERFUSION TO TREAT METASTATIC MELANOMA OF THE EXTREMITY.	BURROUGHS WELLCOME COMPANY
GENERIC: MINOCYCLINE HCL TRADE: MINOCIN	TREATMENT OF CHRONIC MALIGNANT PLEURAL EFFUSION.	LEDERLE LABORATORIES
GENERIC: OXALIPLATIN TRADE: NOT ESTABLISHED	TREATMENT OF OVARIAN CANCER.	AXION PHARMACEUTICALS

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: PAPAVERINE (TOPICAL GEL) TRADE: NOT ESTABLISHED	TREATMENT OF SEXUAL DYSFUNCTION IN SPINAL CORD INJURY PATIENTS.	PHARMEDIC COMPANY
GENERIC: PARA-AMINOSALICYLIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF TUBERCULOSIS INFECTIONS.	JACOBUS PHARMACEUTICAL COMPANY
GENERIC: PILOCARPINE HCL TRADE: NOT ESTABLISHED	TREATMENT OF XEROSTOMIA AND KERATOCONJUNCTIVITIS SICCA IN SJOGREN'S SYNDROME PATIENTS.	MGI PHARMA, INC
GENERIC: POLYMERIC OXYGEN TRADE: NOT ESTABLISHED	TREATMENT OF SICKLE CELL ANEMIA.	CAPMED, USA
GENERIC: PPI-002 TRADE: NOT ESTABLISHED	TREATMENT OF MALIGNANT MESOTHELIOMA.	PLEXUS PHARMACEUTICALS, INC
GENERIC: SODIUM MONOMERCAPTOUNDECAHYDRO-CLOSODODECABORATE TRADE: BOROCELL	FOR USE IN BORON NEUTRON CAPTURE THERAPY IN THE TREATMENT OF GLIOBLASTOMA MULTIFORME.	NEUTRON TECHNOLOGY CORPORATION
GENERIC: SODIUM PHENYLBUTYRATE TRADE: NOT ESTABLISHED	TREATMENT OF SICKLING DISORDERS, WHICH INCLUDE S-S HEMOGLOBINOPATHY, S-C HEMOGLOBINOPATHY, AND S-THALASSEMIA HEMOGLOBINOPATHY.	JOHNS HOPKINS MEDICAL INSTITUTIONS
GENERIC: SOTALOL HCL TRADE: BETAPACE*/**	TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYARRHYTHMIAS. [OCT 30, 1999]	BRISTOL-MYERS SQUIBB
GENERIC: TENIPOSIDE TRADE: VUMON*/**	TREATMENT OF REFRACTORY CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA (ALL). [JUL 14, 1999]	BRISTOL MYERS SQUIBB
GENERIC: TOPIRAMATE TRADE: TOPIMAX	TREATMENT OF LENNOX-GASTAUT SYNDROME.	R. W. JOHNSON RESEARCH INSTITUTE
GENERIC: ZALCITABINE TRADE: HIVID	TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS). [JUN 19, 1999]	ROCHE
GENERIC: 9-CIS RETINOIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.	LIGAND PHARMACUETICALS, INC

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1992 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFD-650, MPN-2 ROOM 279, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ALPRAZOLAM (TABLET)	NOV 27, 1992	
CARBIDOPA AND LEVODOPA (TABLET)	JUN 19, 1992	
CIMETIDINE (TABLET)	JUN 12, 1992	
CORTICOSTEROID *IN VITRO* AND *IN VIVO* INTERIM (TOPICAL)	JUL 01, 1992	
DIFLUNISAL (TABLET)	MAY 16, 1992	
DILTIAZEM HYDROCHLORIDE (TABLET)	MAY 16, 1992	
ESTROPIPATE (TABLET)	AUG 26, 1992	
GEMFIBROZIL (CAPSULE AND TABLET)	JUN 23, 1989	JUN 15, 1992
METOPROLOL TARTRATE (TABLET)	JUN 12, 1992	
NADOLOL (TABLET)	MAY 16, 1992	
NAPROXEN (TABLET)	JUN 12, 1992	
NORTRIPTYLINE HYDROCHLORIDE (CAPSULE)	JUN 15, 1992	
PIROXICAM (CAPSULE)	JUN 15, 1992	
STATISTICAL PROCEDURE FOR BIOEQUIVALENCE STUDIES USING A STANDARD TWO-TREATMENT CROSSOVER DESIGN	JUL 01, 1992	
TERFENADINE (TABLET)	JUN 12, 1992	

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET; ORAL	500MG 7.5MG	91 P-0514/ CP1	SOFTAN	NEW STRENGTH	APPROVED JUN 03, 1992
ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET; ORAL	660MG 10MG	91 P-0004/ CP1	KNOLL	NEW STRENGTH	APPROVED OCT 27, 1992
ALBUTEROL SULFATE CAPSULE, EXTENDED RELEASE; ORAL	EQ 4MG BASE	91 P-0348/ CP1	HAMER	NEW DOSAGE FORM	APPROVED MAR 17, 1992
CHLORZOXAZONE TABLET; ORAL	750MG	91 P-0153/ CP1	MIKART	NEW STRENGTH	APPROVED JUN 03, 1992
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER INJECTABLE; INJECTION	EQ 90MG BASE/100ML EQ 120MG BASE/100ML EQ 180MG BASE/100ML EQ 240MG BASE/100ML EQ 360MG BASE/100ML EQ 480MG BASE/100ML	92 P-0337/ CP1	ABBOTT	NEW STRENGTH	APPROVED OCT 26, 1992
HYDROCORTISONE ACETATE AEROSOL; TOPICAL	2.5%	92 P-0101/ CP1	HOGAN & HARTSON	NEW DOSAGE FORM	APPROVED JUL 08, 1992
NALBUPHINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (2ML/CONTAINER)	92 P-0224/CP	STERLING	NEW STRENGTH	APPROVED SEP 11, 1992

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	5MG/ML (50ML/CONTAINER)	91 P-0387/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 18, 1992
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	10MG/ML (100ML/CONTAINER)	91 P-0387/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 18, 1992
PROPRANOLOL HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	40MG	92 P-0332/ CP1	FLEMINGTON PHARM	NEW DOSAGE FORM	APPROVED NOV 25, 1992
TAMOXIFEN CITRATE TABLET; ORAL	EQ 20MG BASE	92 P-0269/ CP1	KROSS	NEW STRENGTH	APPROVED OCT 26, 1992
TRIAZOLAM SOLUTION; ORAL	0.125MG/5ML	92 P-0048/ CP2	ROXANE	NEW DOSAGE FORM	APPROVED SEP 11, 1992

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/VIAL)	91 P-0076/ CP1	ADRIA	NEW STRENGTH	DENIED FEB 19, 1992

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 12TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES

REFERENCES
NEW INDICATION

I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA

REFERENCES
PATENT USE CODE

U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA

EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODE

U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20232 001	ACETAMINOPHEN; FIORICET W/ CODEINE				NC	OCT 26, 1993
	18828 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	19909 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	20089 001	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	20089 002	ACYCLOVIR; ZOVIRAX				I-71	FEB 26, 1995
	19729 001	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-19		
>ADD>	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	NOV 07, 2006			
			4572909	FEB 25, 2003		NCE	JUL 31, 1997
>ADD>	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	NOV 07, 2006			
			4572909	FEB 25, 2003		NCE	JUL 31, 1997
>ADD>	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	NOV 07, 2006			
			4572909	FEB 25, 2003		NCE	JUL 31, 1997
>DLT>	~~72303 001~~	~~ATENOLOL; ATENOLOL~~	~~3934032~~	~~JAN 20, 1983~~			
>DLT>	~~72304 001~~	~~ATENOLOL; ATENOLOL~~	~~3934032~~	~~JAN 20, 1983~~			
>ADD>	20259 001	ATOVAQUONE; MEPRON	4981874	JAN 01, 2008	U-69	NCE	NOV 25, 1997
	20075 001	BACLOFEN; LIORESAL				ODE	JUN 17, 1999
						NDF	JUN 17, 1995
	20075 002	BACLOFEN; LIORESAL				ODE	JUN 17, 1999
						NDF	JUN 17, 1995
	19851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	19851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	4410520	OCT 18, 2002		NCE	JUN 25, 1996
	20033 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	20033 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	4410520	OCT 18, 2002		NCE	JUN 25, 1996
						NC	MAY 19, 1995
	19001 001	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19001 002	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19001 003	BEPRIDIL HYDROCHLORIDE; BEPADIN	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19002 001	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19002 002	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995
	19002 003	BEPRIDIL HYDROCHLORIDE; VASCOR	RE30577	JUN 08, 1995		NCE	DEC 28, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4311708	JAN 19, 1999	U-3	NC	OCT 30, 1995
>ADD>			4252984	FEB 24, 1998			
>ADD>	19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4311708	JAN 19, 1999	U-3	NC	OCT 30, 1995
>ADD>			4252984	FEB 24, 1998			
	19982 001	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
	19982 002	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
	19548 001	BITOLTEROL MESYLATE; TORNALATE	4336400	JUN 22, 1999	U-5		
	19890 001	BUTORPHANOL TARTRATE; STADOL	4138581	FEB 06, 1998		NDF	FEB 19, 1995
	19847 001	CIPROFLOXACIN; CIPRO	4464378	AUG 07, 2001	U-60	NDF	DEC 12, 1994
			4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
	19857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%	4670444	OCT 01, 2002		NCE	OCT 22, 1992
			4957922	SEP 18, 2007			
			4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
	19858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORIDE 0.9%	4670444	OCT 01, 2002		NCE	OCT 22, 1992
			4957922	SEP 18, 2007			
			4808583	FEB 28, 2006			
			4705789	NOV 10, 2004			
	19537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002		NCE	OCT 22, 1992
	19537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	19537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	19992 001	CIPROFLOXACIN HYDROCHLORIDE; CILOXAN	4670444	OCT 01, 2002	U-36	NCE	OCT 22, 1992
	18713 001	CLOTRIMAZOLE; MYCELEX	4670444	OCT 01, 2002		NDF	DEC 31, 1993
	20118 001	DESFLURANE; SUPRANE				I-81	SEP 29, 1995
	20037 001	DICLOFENAC SODIUM; VOLTAREN	4762856	AUG 09, 2005	U-67	NCE	SEP 18, 1997
	20154 002	DIDANOSINE; VIDEX	4960799	OCT 02, 2007		NDF	MAR 28, 1994
	20154 003	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20154 004	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20154 005	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20155 003	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20155 004	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20155 005	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20155 006	DIDANOSINE; VIDEX				D-18	SEP 25, 1995
	20156 001	DIDANOSINE; VIDEX				D-18	SEP 25, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20027 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NCE	NOV 05, 1992
	20027 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM				NCE	NOV 05, 1992
	20062 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NS	MAY 29, 1995
						I-79	OCT 15, 1995
	20062 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
						I-79	OCT 15, 1995
	20062 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
						I-79	OCT 15, 1995
	20062 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM CD	5002776	MAR 26, 2008		NCE	NOV 05, 1992
			4894240	JAN 16, 2007		NP	DEC 27, 1994
						I-79	OCT 15, 1995
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NS	MAY 29, 1995
						NCE	NOV 05, 1992
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NP	DEC 27, 1994
						NCE	NOV 05, 1992
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	4839177	JUN 13, 2006		NP	DEC 27, 1994
						NCE	NOV 05, 1992
	19946 001	DOXACURIUM CHLORIDE; NUROMAX	4701460	MAR 06, 2005		NCE	MAR 07, 1996
	84499 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
	84500 001	ESTRADIOL; ESTRACE				I-76	SEP 08, 1995
>ADD>	83220 001	ESTROPIPATE; OGEN .625				I-76	NOV 10, 1995
>ADD>	83220 002	ESTROPIPATE; OGEN 1.25				I-76	NOV 10, 1995
>ADD>	83220 003	ESTROPIPATE; OGEN 2.5				I-76	NOV 10, 1995
>ADD>	83220 004	ESTROPIPATE; OGEN 5				I-76	NOV 10, 1995
	19697 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	OCT 01, 2002	U-66		
			4616006	OCT 07, 2003	U-66		
			4544554	JUL 23, 2002	U-66		
			4027019	MAY 31, 1996		NP	JUL 03, 1995
	19697 002	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN	4628051	OCT 01, 2002	U-66		
			4616006	OCT 07, 2003	U-66		
			4544554	JUL 23, 2002	U-66		
			4027019	MAY 31, 1996		NP	JUL 03, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19462 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19462 002	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19527 001	FAMOTIDINE; PEPCID	4283408	AUG 11, 2000		I-69	DEC 10, 1994
	19834 001	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
	19834 002	FELODIPINE; PLENDIL	4264611	APR 28, 1998		NCE	JUL 25, 1996
	20180 001	FINASTERIDE; PROSCAR	4760071	JUL 26, 2005			
			4377584	MAR 22, 2000		NCE	JUN 19, 1997
	20038 001	FLUDARABINE PHOSPHATE; FLUDARA	4357324	NOV 02, 2001		NCE	APR 18, 1996
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003			
			4194009	APR 19, 1994			
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4018895	APR 19, 1994	U-12		
			4771041	JUL 29, 1997			
			4665062	JUL 29, 1997			
			4339445	JUL 29, 1997	U-64		
	19915 002	FOSINOPRIL SODIUM; MONOPRIL	4215113	JUL 29, 1997	U-64	NCE	SEP 27, 1996
	19915 003	FOSINOPRIL SODIUM; MONOPRIL	4337201	JUN 29, 2001		NCE	MAY 16, 1996
>ADD>	20131 001	GADOTERIDOL; PROHANCE	4337201	JUN 29, 2001		NCE	MAY 16, 1996
	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4885363	DEC 05, 2006		NCE	NOV 16, 1997
	20051 001	GLYBURIDE; GLYNASE	4507305	OCT 19, 1999	U-35	I-72	MAY 15, 1995
			4916163	APR 10, 2007			
			4735805	APR 05, 2005		NCE	MAY 01, 1994
			3507961	APR 21, 1992		NP	MAR 04, 1995
			3507954	APR 21, 1992			
			3454635	APR 21, 1992			
			3426067	APR 21, 1992			
	20051 002	GLYBURIDE; GLYNASE	4916163	APR 10, 2007			
			4735805	APR 05, 2005		NCE	MAY 01, 1994
			3507961	APR 21, 1992		NP	MAR 04, 1995
			3507954	APR 21, 1992			
			3454635	APR 21, 1992			
			3426067	APR 21, 1992			
	20055 001	GLYBURIDE; GLUBATE				NP	MAR 04, 1995
						NCE	MAY 01, 1994
	20055 002	GLYBURIDE; GLUBATE				NP	MAR 04, 1995
						NCE	MAY 01, 1994
	19967 001	HALOBETASOL PROPIONATE; ULTRAVATE				D-1	DEC 31, 1994
	19968 001	HALOBETASOL PROPIONATE; ULTRAVATE				D-1	DEC 31, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20250 001	HALOFANTRINE HYDROCHLORIDE; HALFAN				NCE	JUL 24, 1997
						ODE	JUL 24, 1999
	19046 001	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 002	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 003	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19046 004	HYDROCHLOROTHIAZIDE; NORMOZIDE	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 001	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 002	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 003	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19174 004	HYDROCHLOROTHIAZIDE; TRANDATE HCT	4012444	MAR 15, 1994		NCE	AUG 01, 1994
	19261 001	HYDROXYAMPHETAMINE HYDROBROMIDE; PAREMYD				NC	JAN 30, 1995
	20100 001	INSULIN BIOSYNTHETIC HUMAN; HUMULIN 50/50	4001323	JAN 04, 1996		NP	APR 29, 1995
>ADD>	18735 007	IOPAMIDOL; ISOVUE-250				NS	JUL 06, 1995
	19710 002	IOVERSOL; OPTIRAY 240				I-78	JUL 09, 1995
	19710 004	IOVERSOL; OPTIRAY 300	4396598	OCT 26, 2002	U-61	NS	JAN 22, 1995
	19710 005	IOVERSOL; OPTIRAY 350	4396598	OCT 26, 2002	U-62	NS	JAN 22, 1995
						I-74	JAN 22, 1995
	20083 001	ITRACONAZOLE; SPORANOX	4267179	MAY 12, 1998		NCE	SEP 11, 1997
	19645 001	KETOROLAC TROMETHAMINE; TORADOL	4089969	MAY 16, 1997	U-55	NDF	DEC 20, 1994
						NCE	NOV 30, 1994
>ADD>	19700 001	KETOROLAC TROMETHAMINE; ACULAR	4089969	MAY 16, 1997			
	08107 001	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 002	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 004	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	08107 005	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				I-70	DEC 12, 1994
	19732 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006			
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006			
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
						ODE	DEC 31, 1998
	20105 001	LIOTHYRONINE SODIUM; TRIOSTAT	4528287	JUL 09, 2002	U-36	NCE	FEB 21, 1997
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
						I-82	NOV 23, 1995
>ADD>	19487 001	LOPERAMIDE HYDROCHLORIDE; IMODIUM A-D				I-82	NOV 23, 1995
>ADD>	19860 001	LOPERAMIDE HYDROCHLORIDE; IMODIUM A-D	5008294	APR 15, 2008	U-68		
	19940 001	MASOPROCOL; ACTINEX	4695590	SEP 22, 2004		NCE	SEP 04, 1997
						NP	OCT 29, 1995
	20246 001	MEDROXYPROGESTERONE ACETATE; DEPO-PROVERA				NCE	DEC 24, 1992
	19651 001	MESALAMINE; ASACOL				NDF	JAN 31, 1995
						I-67	NOV 14, 1994
	17659 001	METAPROTERENOL SULFATE; ALUPENT					
	19962 001	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
			3876802	APR 08, 1992			
	19962 002	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
			3876802	APR 08, 1992			
	19962 003	METOPROLOL SUCCINATE; TOPROL XL	3998790	APR 08, 1992		NE	JAN 10, 1995
			3876802	APR 08, 1992			
	20208 001	METRONIDAZOLE; METROGEL				NDF	AUG 17, 1995
	20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	AUG 02, 2005		NCE	JAN 22, 1997
	20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	AUG 02, 2005		NCE	JAN 22, 1997
	19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2000		NCE	DEC 24, 1996
			4061779	DEC 06, 1994	U-19		
	19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2000		NCE	DEC 24, 1996
			4061779	DEC 06, 1994	U-19		
	19886 001	NAFARELIN ACETATE; SYNAREL				I-68	FEB 26, 1995
	20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1997		NCE	FEB 13, 1995
						I-68	FEB 26, 1995
	19734 001	NICARDIPINE HYDROCHLORIDE; CARDENE	3985758	OCT 12, 1995		NDF	JAN 30, 1995
						NCE	DEC 21, 1993
	20005 001	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
						NCE	DEC 21, 1993
	20005 002	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
						NCE	DEC 21, 1993
	20005 003	NICARDIPINE HYDROCHLORIDE; CARDENE SR	3985758	OCT 12, 1995		NDF	FEB 21, 1995
						NCE	DEC 21, 1993
	19983 001	NICOTINE; PROSTEP	4946853	AUG 07, 2007	U-56	NS	JAN 28, 1995
	19983 002	NICOTINE; PROSTEP	4946853	AUG 07, 2007	U-56	NS	JAN 28, 1995
	20076 001	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
	20076 002	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994
	20076 003	NICOTINE; HABITROL	5016652	MAY 21, 2008		NDF	NOV 07, 1994

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20150 001	NICOTINE; NICOTROL				NP	APR 22, 1995
20150 002	NICOTINE; NICOTROL				NP	APR 22, 1995
20150 003	NICOTINE; NICOTROL				NP	APR 22, 1995
20165 001	NICOTINE; NICODERM	5004610	APR 02, 2008			
		4144317	SEP 09, 1992		NDF	NOV 07, 1994
20165 002	NICOTINE; NICODERM	5004610	APR 02, 2008			
		4144317	SEP 09, 1992		NDF	NOV 07, 1994
20165 003	NICOTINE; NICODERM	5004610	APR 02, 2008			
		4144317	SEP 09, 1992		NDF	NOV 07, 1994
20066 001	NICOTINE POLACRILEX; NICORETTE DS				NP	JUN 08, 1995
20064 001	NITROFURANTOIN; MACROBID	4798725	JAN 17, 2006			
		4772473	SEP 20, 2005		NDF	DEC 24, 1994
19757 001	NORFLOXACIN; CHIBROXIN	4551456	NOV 05, 2002	U-57		
20087 001	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
20087 002	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000		NCE	DEC 28, 1995
20087 003	OFLOXACIN; FLOXIN	4382892	MAY 10, 2000		NCE	DEC 28, 1995
20087 004	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
20087 005	OFLOXACIN; FLOXIN IN DEXTROSE 5%	4382892	MAY 10, 2000		NCE	DEC 28, 1995
19715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	AUG 04, 2004	U-58	NCE	JUL 31, 1995
18841 004	OXAPROZIN; DAYPRO				NCE	OCT 29, 1997
19828 001	OXICONAZOLE NITRATE; OXISTAT				NCE	DEC 30, 1993
					I-77	SEP 30, 1995
20209 001	OXICONAZOLE NITRATE; OXISTAT				NP	SEP 30, 1995
					NCE	DEC 30, 1993
19775 001	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4765989	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4327725	MAY 04, 1999			
		4092315	MAY 30, 1995		NDF	JAN 29, 1995
19775 002	PRAZOSIN HYDROCHLORIDE; MINIPRESS XL	5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4765989	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4327725	MAY 04, 1999			
		4092315	MAY 30, 1995		NDF	JAN 29, 1995
19157 001	PREDNISOLONE SODIUM PHOSPHATE; PEDIAPRED	4448774	MAY 15, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19627 001	PROPOFOL; DIPRIVAN					
	18703 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	4798846	NOV 01, 1996		I-73	DEC 31, 1994
	18703 002	RANITIDINE HYDROCHLORIDE; ZANTAC 300	4521431	JUN 04, 2002		I-75	MAY 19, 1995
	19675 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4521431	JUN 04, 2002		I-75	MAY 19, 1995
	19766 001	SIMVASTATIN; ZOCOR	4128658	DEC 05, 1995		I-75	MAY 19, 1995
	19766 002	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19766 003	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19766 004	SIMVASTATIN; ZOCOR	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	20166 001	SODIUM THIOSULFATE; SODIUM THIOSULFATE	4444784	APR 24, 2001	U-59	NCE	DEC 23, 1997
	19865 001	SOTALOL HYDROCHLORIDE; BETAPACE				NCE	FEB 14, 1997
>ADD>						NCE	OCT 30, 1997
	19865 002	SOTALOL HYDROCHLORIDE; BETAPACE				ODE	OCT 30, 1999
>ADD>						NCE	OCT 30, 1997
	19865 003	SOTALOL HYDROCHLORIDE; BETAPACE				ODE	OCT 30, 1999
>ADD>						NCE	OCT 30, 1997
>ADD>	19865 004	SOTALOL HYDROCHLORIDE; BETAPACE				ODE	OCT 30, 1999
>ADD>						NCE	OCT 30, 1997
	20063 001	TECHNETIUM TC-99M RED BLOOD CELL KIT; RBC-SCAN				ODE	OCT 30, 1999
	19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE				NP	JUN 11, 1995
	20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX				I-80	SEP 09, 1995
	20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	MAR 08, 2005	U-36	NCE	JAN 30, 1997
	20119 001	TENIPOSIDE; VUMON	4730000	MAR 08, 2005	U-36	NCE	JAN 30, 1997
						NCE	JUL 14, 1997
	19614 003	VERAPAMIL HYDROCHLORIDE; VERELAN				ODE	JUL 14, 1999
	20199 001	ZALCITABINE; HIVID	4863742	SEP 05, 2006	U-3	NDF	MAY 29, 1993
			5028595	JUL 02, 2008	U-65	NCE	JUN 19, 1997
	20199 002	ZALCITABINE; HIVID	4879277	NOV 07, 2006	U-65	ODE	JUN 19, 1999
			5028595	JUL 02, 2008	U-65	NCE	JUN 19, 1997
	19655 001	ZIDOVUDINE; RETROVIR	4879277	NOV 07, 2006	U-65	ODE	JUN 19, 1999
			4837208	FEB 09, 2005			
			4833130	FEB 09, 2005		I-47	MAY 02, 1993
			4828838	FEB 09, 2005		ODE	MAR 19, 1994
	19910 001	ZIDOVUDINE; RETROVIR	4724232	FEB 09, 2005		NCE	MAR 19, 1992
			4837208	FEB 09, 2005			
			4833130	FEB 09, 2005		ODE	MAR 19, 1994
			4818538	FEB 09, 2005		I-47	MAY 02, 1993
			4724232	FEB 09, 2005		NCE	MAR 19, 1992

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19951 001	ZIDOVUDINE; RETROVIR	4837208	FEB 09, 2005			
		4833130	FEB 09, 2005		NCE	MAR 19, 1992
		4818538	FEB 09, 2005			
		4724232	FEB 09, 2005		ODE	MAR 19, 1994

New 13th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7023

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

— subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $55.00 per year.

1. The total cost of my order is $_____. All prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

Please Type or Print

2. _____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

3. **Please choose method of payment.**

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Signature)

(11/92)

4. **Mail To:** Superintendent of Documents, Government Printing Office, Washington, DC 20402-9371.
To **FAX** your charge order, call (202) 512-0019.
To charge your subscription call (202) 783-3238.